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ABSTRACT
After nearly half a century since medical approval, the anthracycline doxorubicin
(DOX) remains one of the most potent and clinically useful anticancer agents. In spite of
its long history, however, the cytotoxic mechanisms of DOX have been debated and remain
controversial. Several well-supported mechanisms will be discussed, such as the potential
to intercalate DNA and induce apoptosis through topoisomerase poisoning, free radical
formation, and DNA cross-linking. While DOX has substantial medical importance, it is
plagued by a life-threatening dose-dependent cardiotoxic side effect associated with
several structural groups. A number of modifications to DOX have been accomplished to
attempt to remove treatment-induced cardiotoxicity, including the reduction of the C-13
carbonyl to a methylene and conversion of the quinone moiety to a less reactive
iminoquinone. This modified form, termed 5-imino-13-deoxydoxorubicin (DIDOX), has
displayed no cardiotoxic side effects in any clinical setting. However, these structural
changes have reduced the potency of the drug more than four-fold.
In this work, six different analogs of DIDOX were synthesized and evaluated for
in vitro cytotoxicity against an array of cancer cell lines. The six analogs were designed to
incorporate reactive moieties attached to the 3'-amine of the daunasamine sugar. Of the six
synthesized, four were at least as cytotoxic as DOX, and several were up to 100-fold more
potent. Preliminary results also suggest that modifications to the 3'-amine attenuate the
multidrug resistance observed during anthracycline treatment. In addition to the synthesis
and preliminary evaluation of new anthracycline analogs, this work explored methods for
vi

improving the synthesis of DIDOX. Specifically, the reduction of DOX’s carbonyl to
produce C-13-deoxydoxorubicin (DeoxyDOX) was explored using six different
sulfonylhydrazones, and the relative production of the reduced form was compared. Four
of the new hydrazones exhibited the potential to improve the overall amount of DeoxyDOX
generated, compared to the currently used methods. In summary, the work described
presents both the findings for the synthesis of potent and non-cardiotoxic derivatives of
doxorubicin that show promise for overcoming multi-drug resistance and potential
improvements toward enhancing the overall yield of DIDOX and related analogs.
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CHAPTER ONE: CYTOTOXICITY, CARDIOTOXICITY, AND CANCER
RESISTANCE: MECHANISMS OF DOXORUBICIN
1.1 Cancer
As population and median age increase, so does the number of individuals who
have been directly affected by cancer (Miller, 2016). Cancer can be characterized as a
disease linked with accelerated cell cycles, genomic alterations, chemotaxis, and invasive
growth, ultimately leading to death if left untreated. As such, cancer has been—and
continues to be—a growing issue amongst developed nations. It is the second leading cause
of death in the United States, with 1.7 million new diagnoses and roughly 600,000 deaths
during 2016 (Siegel, 2016). However, the five-year survival rate for many cancers—such
as breast cancer, leukemia, and all combined childhood cancers—has improved
significantly over the last several decades (DeSantis, 2014). Reasons for better prognoses
are largely the result of improved chemotherapy drugs, surgical techniques, radiation
targeting, and increased diagnosis during earlier stages. However, a significant difficulty
with the use of chemotherapeutics stems from the existence of a vast array of different
tumor subtypes, such as well-differentiated, dedifferentiated, round cell, and pleomorphic.
This is problematic because sensitivity to various therapeutic agents greatly depends on the
subtype (Jones, 2005). For example, tumor response is generally better for patients
diagnosed with round cell liposarcomas compared to those who have well-differentiated or
dedifferentiated liposarcomas.
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1.2 Doxorubicin as a Treatment
One drug currently available to effectively treat cancer is doxorubicin (DOX),
which is classified as a broad-spectrum, anthracycline, antitumor antibiotic. DOX has been
in widespread use for more than 50 years as one of the most effective chemotherapeutics
ever developed (Weiss, 1992). Its mechanisms (section 1.4) involve DNA intercalation,
enzymatic inhibition, free radical generation, DNA alkylation, and cross-link formation.
While DOX is an effective treatment for a wide range of solid and hematologic
malignancies, it is plagued by dose-dependent cardiotoxic side effects, eventually leading
to congestive heart failure (Lefrak, 1973; Cusack, 1993). These cardiotoxic effects (section
1.5) can occur acutely or may develop years after treatments have ceased (Lipshultz, 1991).
Unfortunately, this cardiotoxicity diminishes the duration that DOX can be safely
administered, and a maximum cumulative dose of 450 mg/m2 has been established
(Gottdiener, 1981; Swain, 2003). There are two structural characteristics of DOX that have
been associated with cardiotoxicity: the quinone moiety and the C-13 carbonyl (Olson,
1988; Boucek, 1997). A separate complication with DOX is the onset of drug resistance,
which is a leading basis for the failure of recurrent breast cancer treatment (Boa, 2011). As
a result, attempts have been made to overcome these complications through changes in
delivery mechanism, co-treatment with dexrazoxane, as well as synthetic modifications to
the structure of the anthracycline (sections 1.6 & 1.7.4).
1.3 Anthracycline Structural Features and Semi-Synthetic Analogs
For decades, anthracyclines have been a mainstay chemotherapeutic. The first
anthracycline, Daunorubicin (DNR), was discovered in the early 1960’s after being isolated
as a natural product from several different wild strains of Streptomyces (Minotti, Menna,
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2004). DOX was later isolated in 1969 after mutating a strain of the DNR-producing
Streptomyces peucetius. DOX and DNR have similar structures, both consisting of
tetracyclic aglycone rings as well as a sugar moiety (Figure 1.1). The aglycone is made up
of a quinone and an adjacent hydroquinone, a methoxy moiety, and a carbonyl-containing
side chain. Attached to the tetracyclic aglycone is a 3-amino-2,3,6-trideoxy-L-fucosyl
sugar substituent—called daunosamine—that binds via a glycosidic bond. An important
substituent of the daunosamine is the 3'-amine—the importance of which will be discussed
later. The difference between these two drugs involves a variation in the termination of the
carbonyl side chain: DOX with a primary alcohol and DNR with a methyl group at the C14 position.

Figure 1.1
Structure of four anthracycline anticancer antibiotics. Daunorubicin is
lacking the C-14 terminal alcohol and its analog idarubicin has had the C-4 methoxy
excised. Epirubicin is identical to DOX with the exception of the epimerization of the
daunosamine alcohol.
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While the structures and mechanisms of action of DOX and DNR are very similar,
the minor difference in the carbonyl side chain alters their activity considerably.
Historically, DOX has been used in the treatment of breast cancer, childhood solid tumors,
soft tissue sarcomas, and lymphomas, whereas DNR has been used to treat lymphoblastic
and myeloblastic leukemias (Bernard, 1973; Danesi, 2002; Gruber, 2004; Harashima,
1999; Preisler, 1984; Verweij, 2000).
Although DOX and DNR have medicinal importance, their clinical use has been
limited because of multidirectional cytotoxicity, with cardiotoxicity being the most
detrimental. The search for a better anthracycline has only produced a few clinically useful
analogs, as shown above in Figure 1.1. These include the semi-synthetic DOX analog
epirubicin (EPI) and the DNR analog idarubicin (IDA) (Holdener, 1985; Lopez, 1984;
Daghestani, 1985; Ganzina, 1986).
EPI is a derivative of DOX and is formed by epimerization of the daunosamine
hydroxyl from an axial to equatorial position (Zabudkin, 2014, Patent No. 8,802,830).
Interestingly, this DOX analog is generated from a multistep transformation of DNR.
Initially, the 3'-amine of DNR is protected using trifluoroacetic anhydride followed by
oxidation of the daunosamine hydroxyl to a carbonyl (Figure 1.2). This allows for NaBH4
reduction from the axial direction to produce the epimerized hydroxyl, which is now in the
equatorial position. After deprotection, the carbonyl side chain is brominated, using
bis(N,N-dimethylacetamide) hydrogen tribromide (BDMAT), and then hydroxylated to
generate EPI with an overall yield of 26%. This simple, yet important, structural change
has allowed for a higher and more effective dose, which is now commonly utilized in
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neoadjuvant and adjuvant therapies, such as during treatment for node-positive breast
cancer (Buzdar, 2005; French, 2001).
1) TFAA
2) DBN

NaBH4

NaOH

HCOONa

BDMAT

Figure 1.2
Epimerization of DOX and synthesis of EPI. The amine of DNR is
protected using trifluoroacetic anhydride (TFAA), and then the daunosamine hydroxyl is
oxidized to a carbonyl. Reduction of the carbonyl from the axial direction with NaBH4
generates a hydroxyl that is now in the equatorial position. Following amine deprotection,
monobromination of the carbonyl side chain is accomplished using bis(N,Ndimethylacetamide) hydrogen tribromide (BDMAT) and then EPI is generated after
hydroxylation of C-14.
While EPI is an epimerized derivative of DOX, IDA structurally mimics DNR in
that the methoxy moiety has been removed from the tetracyclic rings (Figure 1.3)
(Zabudkin, 2014, Patent No. 8,846,882). This has been accomplished by first protecting
the 3'-amine before demethylation of the methoxy group. The newly formed phenol is
transformed into a triflate, and a palladium catalyst is employed to complete the reduction.
IDA is obtained, after amine deprotection, in up to 44% overall yield. This seemingly minor
change has allowed IDA to outperform DNR in the treatment of acute myelogenous
leukemia (AML) (Berman, 1991; Vogler, 1992). For instance, during a phase 3 trial,
complete remission of AML was seen in 71% of patients treated with IDA and only 58%
when treated with DNR.
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Figure 1.3
Demethoxylation of DNR to synthesize IDA. First, the amine is protected,
typically with trifluoroacetic anhydride, and then the methoxy group is demethylated. The
resulting phenol is converted into a triflate that is removed via palladium catalyzed
reduction. Finally, the amine is deprotected to obtain IDA.
1.4 Mechanisms of Action
Although nearly half a century of research has gone into trying to understand the
cytotoxic mechanisms employed by DOX, the means by which it acts against cancer
remains under debate (Minotti, 2004). Of the many mechanisms that have been proposed,
only those thought to be most responsible for the anticancer activity will be discussed here.
These include DNA intercalation and enzyme inhibition, production of free radical
facilitated damage, and the formation of cross-links inhibiting cellular proliferation.
Interestingly, each of these mechanisms results in irreversible DNA damage, albeit using
vastly different pathways.
1.4.1 Intercalation and Topoisomerase II Inhibition
One of the most accepted mechanisms of DOX-induced cytotoxicity involves the
inhibition of the enzyme topoisomerase II (TOPOII). In mammalian cells, TOPOII
catalyzes a variety of DNA isomerization reactions, such as catenation, decatenation, and
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relaxation of superhelical twists (Berger, 1996) through the sequence of events depicted in
Figure 1.4. First, TOPOII binds to the G-segment of DNA, leading to a conformational
change in the enzyme. Next, the T-segment and ATP bind to TOPOII triggering another
conformational change and temporary scission of the G-segment. Next, the T-segment is
passed through the split strands and released from the complex. Finally, TOPOII reseals
and releases both the G-segment and ADP to regenerate the starting enzyme.

DOX
Figure 1.4
TOPOII-mediated DNA cleavage. TOPOII initially binds to the Gsegment of DNA and then brings in the T-segment. It then uses ATP to open the G-segment
and passes the T-segment through. The cleaved strands become re-fused and the T-segment
is released from the complex, followed by the release of the G-segment or additional
unwinding. This process repeats to unwind DNA. DOX inhibits this process by inducing
covalently bound TOPOII-DNA complexes with the G-segment of DNA. (figure modified
from Nitiss, 2009).
DOX stabilization of the TOPOII-DNA complex after strand scission is one of the
mechanisms proposed to be responsible for its cytotoxic activity. Stabilizing this complex
inhibits the enzyme from rebinding the G-segments and leads to irreversible strand breaks
(Tewey, 1984). DOX facilitates the formation of these complexes by providing a unique
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structural change in the DNA that allows a tyrosine in TOPOII to act as a nucleophile and
bind to a DNA base pair (Gao, 2014; Mueller-Planitz, 2007). The ability of DOX to
facilitate TOPOII binding relies on its ability to intercalate in between DNA strands
(Figure 1.5) (Capranico, 1990). The tetracyclic structure is crucial for intercalation, as xray crystallography has determined that ring D occupies the intercalation site and that rings
B and C form hydrophobic interactions with adjacent base pairs. The daunosamine moiety
and ring A reside in the minor groove and provide stability for the formation of the DOXTOPOII-DNA complex through hydrogen bonding (Frederick, 1990; Wang, 1987).
Damage associated with TOPOII-DNA complexes induces growth arrest followed by
programmed cell death (Harris, 2001).

Figure 1.5
DOX-DNA intercalation. The terminal ring of DOX’s tetracyclic moiety
sits in between the double strands of DNA and the remaining rings stabilize this
intercalation. The daunosamine sugar rests in the minor grove of DNA and hydrogen bonds
to adjacent base pairs. (figure modified from Frederick, 1990)
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1.4.2 Free Radical-Mediated Apoptosis
An intrinsic property of DOX is its ability to catalyze the generation of intracellular
reactive oxygen species (ROS). The mechanism of ROS production occurs catalytically as
a result of the structurally encompassed quinone moiety present in DOX. The quinone is
capable of undergoing a single-electron shuttling mechanism (i.e. redox cycling) mediated
through NADPH, iron-quinone complexes, and nitric oxide synthase mechanisms (Bachur,
1979; Bachur, 1977; Cummings, 1992; Rajagopalan, 1988; Vásquez-Vivar, 1997).
Initiation of the NADPH redox cycling cascade occurs when NADPH reduces a
flavoprotein, such as flavin adenine dinucleotide, by transfer of a lone hydride (Figure 1.6)
(Shen, 1999). A successive single-electron transfer from the reduced flavoprotein to the
quinone of DOX then forms a reactive semi-quinone that readily transfers its electron to
molecular oxygen, generating superoxide radicals.

NADPH Cytochrome
P-450 Reductase

Figure 1.6
DOX production of reactive oxygen species. (A) Quinone redox cycling
catalytically produces superoxides that may directly lead to cellular damage or indirectly
through formation of peroxides. (B) Peroxides react with free iron or superoxides to form
highly reactive hydroxyl radicals.
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As shown by Figure 1.6, these superoxide radicals can follow a Haber-Weiss style
mechanism to create more damaging hydroxyl radicals. Other mechanisms have been
suggested for iron-catalyzed ROS production, such as a Fenton-type reaction where Fe2+
is oxidized to Fe3+ by donating an electron to a peroxide species that is produced during
redox cycling. These reactive hydroxyl products cause DNA base pair damage through
oxidation, resulting in the dysfunction of DNA synthesis (Doroshow, 1986).
1.4.3 DNA Alkylation and Virtual Cross-Linking
Another mechanism of DOX cytotoxicity involves the ability to form covalent
DNA adducts using quinone-radical produced formaldehyde. After DOX diffuses into the
nucleus of a cell, formaldehyde-mediated dimerization occurs, followed by hydrolysis to
create a reactive Schiff base (Figure 1.7) (Cutts, 2003; Swift, 2006; Taatjes, 1998; Taatjes,
1999; Zeman, 1998). In order to support the proposed mechanism, a synthetic dimer was
first isolated by treating DOX with excess formaldehyde, then hydrolyzed in a phosphate
buffer. Next, DNA was treated with this hydrolyzed-dimer and exhibited similar DNAdrug adducts as with free, unmodified DOX.
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Figure 1.7
Formaldehyde-mediated dimerization. (A) The reaction of two DOX
molecules with formaldehyde leads to the formation of a dimer with two methylene groups
and a binding oxazolidine at the 3'-nitrogen of the daunosamine sugar. (B) Hydrolysis of
the dimer generates two DOX molecules containing an unstable hemiaminal, which goes
on to form a Schiff base.
While normally observed in low quantities, redox cycling-mediated oxidation
results in a spike of cellular formaldehyde. For example, peroxides formed during redox
cycling undergo a Baeyer-Villiger type oxidation with DOX at the C-13 position (Figure
1.8). This ester intermediate was able to be isolated by treating DOX with dithiothreitol
and hydrogen peroxide (Taatjes, 1997). Mass spectrometry results suggest that the
hydroxymethyl of the ester was able to leave as reactive formaldehyde by producing a
carboxylic acid in place of the carbonyl side chain of DOX. Other carbon sources, such as
spermine, can also undergo ROS-mediated oxidation to release formaldehyde.
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Figure 1.8
Formation of formaldehyde from DOX oxidation. (A) Baeyer-Villiger
oxidation of DOX with hydrogen peroxide forms an ester intermediate. (B) The oxidized
intermediate then decomposes to produce formaldehyde and a carboxylic acid.
During intercalation, a combination of hydrogen bonding and the newly formed
Schiff base produce a virtual interstrand cross-link (Figure 1.9). The cross-linking initiates
when a guanine 2-amino group in the minor groove of DNA covalently attaches to the
daunosamine sugar as a monoadduct. After covalent modification, hydrogen bonding of
DOX’s C-9 alcohol to an opposing guanine base binds the DNA tightly together, forming
what is known as a virtual cross-link. While true interstrand cross-links covalently attach
to both DNA strands, the hydrogen bonding and monoadduct of the virtual cross-link
produces analogous functionality (Barthel, 2016). Such cross-linking considerably slows
DNA strand exchange and inhibits cellular proliferation.
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Figure 1.9
Formation of virtual cross-links. (A) Guanine acts as a nucleophile and
binds to the Schiff base present on DOX. (B) After covalent attachment to one guanine,
the virtual cross-link forms through hydrogen bonding of an opposing guanine.
1.5 Mechanisms of Cardiotoxicity
While DOX is an effective anticancer agent, its use is restricted by the onset of
cardiotoxicity, of which the mechanisms have been extensively studied (Olson, 1988;
Kumar, 2001). One mode of DOX-induced cardiotoxicity includes the formation of an
alcohol-containing metabolite that accumulates within cardiac tissue, which results in ionpump disruption and decreased cardiac contractility. Along with the DOX metabolite, the
quinone moiety has been implicated in generating cardiotoxic side effects—via the
formation of ROS—along with the ability of DOX to inhibit important antioxidant
enzymes located in cardiac tissue.
1.5.1 Doxorubicin’s Cardiotoxic Alcohol Metabolite
After treatment, roughly 50% of DOX becomes metabolized before being excreted.
Unfortunately, the main alcohol metabolite, doxorubicinol (DOXol), has a large role in
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DOX associated cardiotoxicity (Figure 1.10) (Kassner, 2008; Schaupp, 2015). Formed via
enzymatic two-electron reduction of the C-13 carbonyl, accomplished by the enzyme
carbonyl reductase, DOXol acts as a potent inhibitor of various membrane-associate ion
pumps. These include calcium pumps in cardiac sarcoplasmic reticulum (SR),
sodium/potassium pumps of cardiac sarcolemma, and F0F1 proton pumps of cardiac
mitochondria (Robert Jr, 1987). This leads to considerable disruption as ion pumps are vital
for muscle relaxation and cell signaling. Appreciable inhibition of SR calcium pumps
occurs at relatively low concentrations of DOXol (IC50 <5g/mL), whereas, DOX exhibits
no measurable inhibition until concentrations exceed 100-fold that of DOXol (Olson,
1988).
As well as inhibiting ion pumps, DOXol has a higher propensity than DOX to
accumulate within cardiac tissue, where the severity of cardiomyopathy is directly
correlated to increasing concentration (Dodd, 1993; Stewart, 1992). DOXol accumulation
into cardiac tissue has been established to occur in a time-dependent manner, determined
using rabbit cardiac tissue. Specifically, DOXol demonstrated consistent decreases in
myocardial contractility, cardiac relaxation, and an increase in muscle stiffness over time
(Mushlin, 1993). The continual accumulation of DOXol results in chronic cardiotoxicity
and eventually leads to life-threatening congestive heart failure.

15

Figure 1.10 Formation of doxorubicin’s cardiotoxic alcohol metabolite. The
formation of DOX’s cardiotoxic alcohol metabolite, DOXol, is produced by enzymatic
carbonyl reductase-mediated reduction of the C-13 carbonyl. This metabolite readily
accumulates in cardiac tissue and disrupts normal function.
1.5.2 Quinone Redox Cycling-Mediated Cardiotoxicity
Cardiac myocytes have been shown to be more susceptible than other cells to
oxidative damage (Burton, 1984). In the presence of ROS, such as hydroxyl radicals,
cardiac cell length shortens and ultimately leads to irreversible hypercontraction, followed
by cytolysis. As a result of this sensitivity, the quinone moiety of DOX has been linked to
cardiotoxicity due to catalyzing the production of ROS (Kumar, 2001). This becomes
especially problematic considering the ability of DOX to accumulate and collect in cardiac
tissue, as mentioned earlier. Another source of cardiac sensitivity stems from low levels of
cardiac catalase activity to protect against hydrogen peroxide. This forces cardiac tissue to
rely on glutathione peroxidase and superoxide dismutase for free radical scavenging.
However, DOX inhibits these two critically important enzymes, leaving the cardiac tissue
vulnerable to oxidative damage (Sawyer, 1999; Siveski-Iliskovic, 1995; Doroshow, 1980;).
Notably, changes in enzymatic antioxidant capacity and increases in cardiac oxidative
stress occur as early as the first dose of DOX (Li, 2002).
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1.5.3 Nitric Oxide Synthase-Dependent ROS Formation
Reduction of the quinone moiety has been proposed to follow several different
mechanisms. One proposal involves the binding of DOX to the reductase domain of
endothelial nitric oxide synthase (eNOS) followed by subsequent reduction (VásquezVivar, 1997). The Km value of eNOS for DOX is 50 times lower than that of other reductase
enzymes, such as cytochrome P450 reductase, which suggests that eNOS is likely
responsible for the majority of reductions at low DOX concentrations. Furthermore, DOXeNOS binding results in an increased production of superoxide and successive ROS
species, which subsequently react with nitric oxide to form an even stronger oxidizing
agent: peroxynitrite (Weinstein, 2000; Beckman, 1996). Within cardiac tissue, the
formation of peroxynitrite is especially problematic as nitric oxide is maintained at high
concentration due to its involvement in the regulation of contractility, endothelial integrity
and platelet aggregation (Loscalzo, 1995). The formation of this potent oxidant
significantly increases protein nitration and leads to acute cardiac disfunction (Kooy,
1997).
1.5.4 Iron Regulatory Protein Inhibition
Deviation from proper cellular iron homeostasis is a contributing factor for both
chronic and acute cardiotoxicity (Minotti, 1999; Minotti, 2001; Myers, 1998). Disruption
of iron regulation during treatment occurs when the drug’s metabolite, DOXol, delocalizes
iron from iron regulatory protein-1 as well as DOX-mediated ROS that disables iron
regulatory protein-2. For example, rats exposed to clinically equivalent plasma
concentrations of DOX (7.5-10 µM) exhibit inactivation of iron regulatory protein-2
(Minotti, Recalcati, 2004). The inhibition of these regulatory proteins prevents cardiac cells
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from recognizing changes in iron availability, consequently disrupting proper homeostasis.
This can be detrimental because moderately reactive peroxides and superoxides formed
during treatment will react with free iron, via a Fenton-type reaction, to produce highly
reactive hydroxyl radicals.
1.6 Overcoming Cardiotoxicity
Years of research have been dedicated to eliminating the cardiotoxic side effects of
DOX. The following discussion describes the most promising and clinically relevant
approaches that have demonstrated a reduction in cardiotoxicity, such as the encapsulation
of DOX in a pegylated liposome, which reduces its free concentration and uptake into
myocytes. Another approach uses co-administration with the ROS scavenging drug,
dexrazoxane, to limit quinone-cardiac damage. Additionally, synthetic modifications of the
anthracycline structure, as seen in EPI and IDA will be discussed. Finally, while these
earlier methods have attenuated cardiotoxicity, only direct synthetic modifications to
DOX’s quinone and C-13 carbonyl have led to a completely non-cardiotoxic anthracycline.
1.6.1 Pegylated Liposomal Doxorubicin
One attempt to curb DOX-induced cardiomyopathy has been to encapsulate the
drug within 100 nm diameter liposomes coated with polyethylene glycol (PEG) bound to
the outer surface, which has been marketed as DOXil (Figure 1.11) (Batist, 2001; O’brien,
2004; Wibroe, 2016). The encapsulatoin protects against metabolic degradation and
excretion by reducing the plasma concentration of free DOX compared to that of nonencapsulated therapies, allowing for a longer circulation time (Gabizon, 1994). These
effects are the result of the hydrophilic PEG surface, which have been shown to reduce
opsonization and reticuloendothelial uptake (Allen, 1991).
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Although not completely understood, there is evidence suggesting that DOXil
preferentially accumulates and releases DOX within tumor tissue, likely due to leaky
vasculature and elevated ammonia concentrations (Chauhan, 2012). After 48 hours of
incubation in either plasma or buffer, less than 5% of DOX diffuses from DOXil, whereas
more than 35% is released when 5 mM ammonia, a biologically relevant concentration, is
present (Silverman, 2015). The limited potential to form free DOX and preferred uptake
into cancerous tissue helps prevent cardiac drug-accumulation and subsequent
cardiotoxicity. For example, in a clinical study where 42 patients were administered doses
exceeding that of 500 mg/m2 DOXil and monitored for changes in left ventricular ejection
fraction (LVEF), it was found that only five of these patients had a drop of 10% or more
LVEF post-treatment (Safra, 2000). This demonstrated that treatment of encapsulated
DOX, rather than free DOX, provides some level of cardiac protection.

Figure 1.11 Pegylated liposome of DOXil. DOX (red dots) is encapsulated in a lipid
bilayer coated with PEG. The lipid bilayer prevents DOX release outside tumor site and
the PEG shell inhibits immune or metabolic removal of the complex.
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1.6.2 Dexrazoxane Co-Treatment
Co-administration of DOX with ROS scavengers has been another approach used
to mitigate DOX-induced cardiotoxicity (Lipshultz, 2010). One ROS scavenger,
dexrazoxane (DEX, Figure 1.12), used in this manner for more than 20 years, reduces ROS
generation by inhibiting the formation of iron-quinone complexes (Hasinoff, 1998). In
order to prevent these complexes, DEX must first undergo enzymatic hydrolysis, mediated
by dihydroorotase, to open both rings. Once in the ring-opened form, it detaches iron from
the quinone and chelates intracellular iron, which prevents complex formation (Junjing,
2010; Šimůnek, 2008). Furthermore, DEX scavenges for hydroxyl and superoxide radicals
in its parent, ring-closed form (Galetta, 2010). The effectiveness of this approach was
demonstrated by comparing atrial contractility of rats administered DEX prior to chronic
anthracycline treatment (Cusack, 2006). From this study, DEX treated rats had roughly 3
times greater atrial contractility (27 g/s) compared to those not given the ROS scavenger
(10 g/s) and had similar contractility to a control group (33 g/s). As a result, coadministration of DEX attenuated the risk of cardiotoxicity without impairing DOX
cytotoxicity.

Open-Ring Form

Dexrazoxane

Dihydroorotase

Dihydroorotase

Figure 1.12 Activation of dexrazoxane for iron-chelation. Opening both rings on
dexrazoxane requires dihydroorotase-mediated hydrolysis. Once in the open form, DEX
can inhibit quinone-iron complexes by chelation of intracellular iron, thus preventing ROS
formation.
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1.6.3 Epirubicin and Idarubicin Analogs
In an effort to overcome the cardiotoxic nature of anthracyclines, the structurally
modified analog EPI was developed (Figure 1.13). It was found that EPI produced similar
antitumor activity as DOX, while being less cardiotoxic (Torti, 1986; Weiss, 1992). In fact,
it was found that roughly 180 mg/m2 more EPI was required before similar cardiotoxic
injuries occurred. The single epimerization of the daunosamine hydroxyl decreases
cardiotoxicity due to an increased occurrence of glucuronidation: the attachment of
glucuronic acid via a glycosidic bond to the daunosamine hydroxyl group. The amplified
glucuronidation helps facilitate the excretion of EPI and as a result shortens the elimination
phase, generating superior plasma clearance than DOX.
An additional anthracycline analog, IDA (Figure 1.13), has also been studied for
its potential to be less cardiotoxic (Daghestani, 1985; Ganzina, 1986). This analog is
similar to DNR with the only difference stemming from the elimination of the C-4 methoxy
on the tetracyclic moiety. The removal of this group provides better affinity toward lipids
allowing for the possibility of oral administration instead of intravenously. While the in
vivo studies show that, mass to mass, this analog produces more cardiotoxicity than DNR,
overall cardiotoxicity is reduced because patients only require one fifth of IDA for similar
anticancer effects.
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Figure 1.13 Structures of Epirubicin and Idarubicin. Epirubicin is a DOX based
analog with a single epimerization of the daunosamine hydroxyl. Idarubicin is a
demethoxylated analog of DNR.
1.6.4 Synthetic Modifications of Anthracycline Core to Overcome Cardiotoxicity
Synthetic chemists have sought to alleviate cardiotoxicity by removing the
structural moieties responsible for inducing the undesired effects. Since metabolism of the
C-13 carbonyl to the corresponding alcohol has been proposed to result in cardiac
dysfunction, this was a logical functional group to attempt modifying. One successful
modification followed a Wolff-Kishner style reduction of the C-13 carbonyl to a
methylene, forming 13-deoxydoxorubicin (DeoxyDOX, Figure 1.14) (Smith, 1978).
While DeoxyDOX, entered into clinical trials by GEM Pharmaceuticals under the name
“GPX-100”, does not interact with carbonyl reductase to form DOXol, a phase 2 clinical
trial was terminated early because several patients began displaying signs of cardiac
disfunction (Holstein, 2015).
The lack of success with DeoxyDOX indicated that the quinone moiety also has an
integral role in the onset of cardiotoxicity. As a result, a second-generation analog, 5imino-13-deoxydoxorubicin (DIDOX), was developed by converting the quinone of
DeoxyDOX to a less reactive iminoquinone. The new compound is termed “GPX-150” by
GEM Pharmaceuticals (Figure 1.14) (Acton, 1981). The combination of these structural
modifications prevents the formation of the cardiotoxic alcohol metabolite and ROS from
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quinone redox cycling. In experiments using rabbit heart models, no sign of cardiotoxicity
was observed during or after DIDOX treatment (Frank, 2016; Olson, 2007; Hohl, 2013).
One experiment revealed that left atrial contractility was reduced by roughly half when
treated with DOX (P < 0.001) compared to those treated with DIDOX.
While DIDOX decreases cardiotoxicity, the structural alterations have imposed a
cytotoxic disadvantage: DIDOX is about four-fold less potent than DOX. For instance, in
a [3H]-thymidine incorporation assay using human promyelocytic leukemia (HL60) cells,
DIDOX exhibited an IC50 of 593 nM, whereas that of DOX was 148 nM (Holstein, 2015).
A separate shortfall of DIDOX involves the synthesis, where the reduction to obtain
DeoxyDOX has a yield as low as five percent. The combination of low yield and
suppressed potency makes DIDOX a much more expensive chemotherapeutic to
manufacture.

Figure 1.14 Synthesis of DIDOX. The initial step involves an imine condensation at the
C-13 carbonyl using benzenesulfonyl hydrazide. DeoxyDOX is then formed after a WolffKishner reduction using sodium cyanoborohydride and pyridinium p-toluenesulfonate. The
final step to obtain DIDOX uses concentrated ammonia to convert the quinone to an
iminoquinone.
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1.7 Cancer Resistance
The development of multidrug resistance (MDR), such as resistance to DOX, has
led to the failure of life-saving therapies, notably when attempting to treat recurring breast
cancer (Bao, 2011). Characteristic of MDR is the overexpression of P-glycoprotein (PGP)
(Frézard, 2001; Loe, 1996). It has been well documented that PGP is involved in molecular
efflux and that this efflux capacity is potentially an underlying cause for MDR. Glutathione
has also been implicated with assisting drug efflux leading to MDR. Also, alterations to
the mechanisms and structure of TOPOII contribute to resistance of anthracycline
treatment. These important mechanisms of resistance to DOX will be discussed in the
sections that follow.
1.7.1 P-Glycoprotein-Mediated Resistance
The human ATP-binding cassette (ABC) transporter family has drawn interest due
to its possible role in MDR. This family contains a variety of structurally related membrane
proteins responsible for moving substrates against their concentration gradients, notably
across intra- and extracellular membranes (Dean, 2001). Overexpression of one member
of the ABC transporter family, PGP, is observed in drug resistant cancer lines and
continues to be the focus of intense research (Cordon-Cardo, 1989; Koziolová, 2016).
Pharmacokinetic studies determined that PGP is able to recognize a broad spectrum of
drugs, such as DOX, and transport them outside the cell (Figure 1.15) (Lin, 2003).
Remarkably, when previously sensitive cells were transfected with a PGP expression
vector, their sensitivity to DOX decreased up to 15-fold (Grant, 1994). Not only does PGP
have a preference for molecules containing multiple aromatic rings, efflux occurs roughly
three times faster if the molecule contains a basic center able to accept a proton (Priebe,
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1993). Both of these structural features are consistent with that of DOX and understandably
allow for preferential efflux of this drug. In addition, it has become evident that PGP
overexpression occurs in cell lines expressing resistance to drugs such as DOX, which
results in reduced intracellular concentrations of DOX and the failing of its anticancer
potential (Grant, 1994).

Figure 1.15 P-Glycoprotein efflux. Although DOX passively diffuses across the cell
membrane, PGP efficiently recognizes, binds, and transports the drug back into the
extracellular space. This efflux protein is up-regulated in MDR cancer cells.
1.7.2 Glutathione MDR
Glutathione S-transferase (GST) is a ubiquitous cytoplasmic enzyme responsible
for xenobiotic biotransformation and metabolism. The increased expression of one
subclass, GST, is linked to numerous cancer lines resistant to DOX (Goto, 2001). The
reduced form of glutathione (GSH) has a function in facilitating the efflux of DOX through
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the formation of DOX-GSH adducts, which are recognized by ABC transporters. GST
has a role in the formation of these adducts, however, a specific mechanism has yet to be
proposed. To demonstrate GST-facilitated resistance, MCF-7 human breast cancer cells
were transfected with the GSTgene and evaluated for resistance (Moscow, 1989). These
cells expressed resistance correlating to the concentration of GST, where lower level
provided roughly three-fold resistance and higher levels expressed nearly 4.5-fold
resistance. Additionally, GST accumulates inside the nucleus of cells, where it exhibits
peroxidase activity to scavenge DOX-induced ROS, limiting DNA lesions and reducing
activity.
1.7.3 Topoisomerase II-Mediated Resistance
Several tumors, such as small- and non-small cell lung cancer, develop MDR
because of reduced TOPOII activity (Cole, 1991). Evidently, a decreased concentration or
activity of this enzyme inhibits the effectiveness of DOX, due to one of its primary
mechanisms relying on the interaction and inhibition of TOPOII. For example, a resistant
KB/VM-4 cancer line, developed by growing HeLa cells under 31-53 nM Teniposide
pressure, expressed only 21% relative TOPOII concentrations. This allowed for an 11-fold
increase in resistance to DOX (Matsuo, 1990). While conclusive evidence for one
mechanism over the other has yet to be offered, the onset of MDR is likely a combination
of those described.
1.7.4 Daunosamine Functionalization to Overcome Multidrug Resistance
As mentioned previously, DOX covalently binds to DNA through an aldehyde
intermediate produced from free radical reactions. However, DOX-resistant cells have a
high expression of antioxidants and drug efflux proteins that prevent this important
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cytotoxic event from occurring (Gariboldi, 2003). Additionally, synthetic modifications of
the 3'-amine on DOX have been able to prevent the inhibition of DNA cross-links and PGP
drug efflux (Beckman, 1988; Bielack, 1994; Streeter, 1986; Taatjes, 2001).
Modification to the 3'-amine of DOX has included a variety of moieties that contain
an intrinsic ability to form covalent DNA adducts without relying on metabolic activation
(Wassermann, 1986). One example is the modified drug 2-pyrrolinodoxorubicin (PDOX),
synthesized with a five-membered pyrrolino ring on the daunosamine sugar (Stepankova,
2011; Studenovsky, 2011). This pyrrolino moiety acts as a masked aldehyde capable of
forming covalent bonds with DNA (Figure 1.16) (Nagy, 1996). The formation occurs
when the nitrogen from a DNA base pair, such as guanine, acts as a nucleophile to form an
aminal adduct with the iminium carbon. After modification, hydrogen bonding occurs with
an adjacent guanine base to complete the DNA virtual cross-link (Cullinane, 1993). Such
functionalization has been able to overcome MDR and will be discussed in further detail
in the next chapter.
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Figure 1.16 PDOX DNA cross-linking. (A) Guanine acts as a nucleophile and reacts
with the pyrroline to neutralize the reactive iminium. (B) After initial attachment of one
guanine, hydrogen bonding with an adjacent guanine completes the virtual cross-link.
1.8 Concluding Remarks
While the cardiotoxic side effects limit use, anthracyclines such as DOX remain
important in anticancer therapies. The push toward a better anthracycline has been a focus
for decades and continues to be of interest. The successes of several methods and analogs
have given hope that one day a clinically useful anthracycline will be available without the
alarm of cardiac damage. The work described in this thesis has a directed focus on
combining the success of synthetic modifications to remove the potential of cardiotoxicity
with that of improving anthracycline efficacy against cancer.
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CHAPTER TWO: SYNTHESIS AND BIOLOGICAL EVALUATION OF POTENT
AND POTENTIALLY NON-CARDIOTOXIC ANTHRACYCLINE ANALOGS
2.1 Introduction
Anthracycline drugs have been used in anticancer therapies for decades, the most
clinically important being doxorubicin (DOX) (Weiss, 1992). DOX has proven to be
effective against a broad spectrum of solid and hematologic malignancies and is often used
in combination with various other chemotherapeutic agents (Danesi, 2002; Gruber, 2004;
Verweij, 2000). Although the exact mechanism of DOX is still highly debated, the means
of antiproliferation have been suggested to follow a variety of pathways. One supported
mechanism involves the intercalation of DOX between DNA double strands followed by
topoisomerase II poisoning, leading to irreversible DNA scissions (Capranico, 1990,
Tewey, 1984). Additionally, DOX contains a quinone moiety capable of catalyzing the
production of intracellular reactive oxygen species (ROS) through NADPH-mediated
single-electron shuttling, iron-quinone complexes, or nitric oxide synthase (Cummings,
1992; Shen, 1999; Vásquez-Vivar, 1997). These reactive species generate DNA base pair
damage and initiate lipid peroxidation. Another characteristic mechanism involves DNA
alkylation and the formation of virtual cross-links (Cutts, 2003; Taatjes, 1998). When DOX
enters the cell, it reacts with formaldehyde to create a Schiff base on the daunosamine
moiety, allowing it to covalently bind to DNA followed by hydrogen bonding to adjacent
DNA bases.

43
While the effectiveness of DOX is well accepted, its use is severely limited due to
the onset of dose-dependent carditoxicity that leads to the eventual outcome of congestive
heart failure (Lefrak, 1973; Cusack, 1993). This cardiotoxicity restricts the extent that DOX
can be utilized, as the maximum cumulative dose has been established at 450 mg/m2
(Swain, 2003) The structural moieties responsible for this side effect have been determined
to include both the C-13 carbonyl as well as the quinone (Figure 2.1) (Olson, 1988;
Boucek, 1997). When the C-13 carbonyl is reduced to an alcohol, mediated by the enzyme
carbonyl reductase, it forms the major DOX metabolite doxorubicinol (DOXol) (Kassner,
2008; Robert Jr, 1987). This metabolite accumulates in cardiac tissues where it acts as a
potent inhibitor of various membrane-associated ion pumps, such as calcium pumps in
cardiac sarcoplasmic reticulum, sodium/potassium pumps of cardiac sarcolemma, and F0F1
proton pumps of cardiac mitochondria.

Figure 2.1
DOX and the cardiotoxic metabolite doxorubicinol. Single-electron
reduction of the quinone moiety of ring C catalyzes the production of cardiac damaging
ROS. The alcohol metabolite, DOXol, is formed by carbonyl reductase-mediated reduction
of DOX’s C-13 carbonyl, which then accumulates and inhibits ion pumps of cardiac tissue.
While quinone-produced ROS is part of the mechanism of DOX cytotoxicity,
cardiac myocytes have a disproportionate susceptibility to this oxidative damage compared
to that of other cells (Burton, 1984; Kumar, 2001; Sawyer, 1999; Siveski-Iliskovic, 1995).
This stems from cardiac cells expressing low levels of catalase activity in combination with
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the inhibitory effect of DOX toward glutathione peroxidase, superoxide dismutase, and
other ROS-scavenging enzymes. In order to minimize the cardiotoxic side effects, DOX
has been co-administered with dexrazoxane, a ROS scavenger. Additionally, encapsulation
with liposomes coated with polyethylene glycol proved helpful to decrease uptake into
cardiac tissue, which subsequently reduces cardiotoxicity (Batist, 2001; O’brien, 2004).
However, neither of these methods have been able to completely eliminate cardiotoxicity
because the two cardiotoxic moieties responsible remain intact.
A separate complication of DOX treatments is the development of multidrug
resistance (MDR), the onset of which has made previous life-saving treatments ineffective,
as seen when attempting to treat recurring breast cancer (Bao, 2011; Grant, 1994). Such
resistance was shown in one study using BALB/c mice, where metastatic tumors of murine
mammary carcinoma did not exhibit growth arrest when treated with DOX, as expected
with cells displaying MDR. While there is not a complete understanding of MDR, a strong
correlation between the overexpression of membrane transporters, such as P-glycoprotein
(PGP), and resistance is well documented (Frézard, 2001; Loe, 1996). Not only does PGP
recognize and efflux a broad spectrum of drugs, including DOX, but it also has a preference
for drugs that contain multiple aromatic rings and a basic nitrogen (Priebe, 1993). Both
features are consistent with the structure of DOX and, as such, render efflux particularly
favorable for this drug.
Successful synthesis of a non-cardiotoxic DOX analog was achieved in previous
work (Scheme 2.1) (Frank, 2016; Olson, 2007; Hohl, 2013). This was accomplished
through a reduction of the C-13 carbonyl to a methylene followed by the conversion of the
highly reactive quinone to a less reactive iminoquinone, forming the final product, 5-imino-
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13-deoxydoxorubicin (DIDOX). These modifications prevent the formation of the
cardiotoxic DOXol metabolite and inhibit the production of quinone-ROS. Notably,
DIDOX has been investigated for signs of cardiotoxicity using rabbit heart models and in
clinical trials in humans, and both have revealed no cardiac injury. In-human studies found
that DIDOX concentrations as high as 265 mg/m2 could be administered without any sign
of cardiotoxicity, even if the patient had previously been treated with anthracyclines
(Holstein, 2015). However, these modifications come with a cytotoxic disadvantage, as
DIDOX is, on average, four times less potent than the unadulterated parent compound. For
example, [3H]-thymidine incorporation assays reported DIDOX to have an IC50 of 593 nM
against HL60 cells, whereas DOX had an IC50 of 148 nM against the same cell line.
In order to synthesize DIDOX, the C-13 carbonyl of DOX first condenses with
benzene sulfonylhydrazide (NH2NHSO2Ph) to form a hydrazone-DOX, in very good yield
(Smith, 1978). However, the Wolff-Kishner reduction of this hydrazone is incredibly poor,
generating the methylene in a yield as low as 5%. While the reducing agent, NaBH3CN, is
relatively mild, the high temperature and acidic pyridinium p-toluenesulfonate (PPTS)
leads to glycoside hydrolysis, lowering the yield of deoxygenated DOX. Following
reduction, the quinone carbonyl is replaced with an imine, in moderate yield, by
condensation with concentrated ammonia.
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Scheme 2.1 Synthesis of DIDOX. The carbonyl of DOX is reduced to a methylene
using a modified Wolff-Kishner reduction. An initial imine condensation occurs using
NH2NHSO2Ph, which is then reduced using NaBH3CN/PPTS in yields as low as 5%.
Afterwords, the quinone is converted to an iminoquinone using 7 N ammonia.
The purpose of this research is to synthesize analogs of DIDOX in order to increase
the cytotoxic potency, remove the potential for MDR, and remain non-cardiotoxic.
Analysis of literature reports suggests that this can be accomplished by modification of the
daunosamine amine to allow for DNA cross-links during intercalation, which has allowed
up to a 1000-fold increase in DOX cytotoxicity in certain instances (Acton, 1984; Nagy,
1996). For example, 2-pyrrolinodoxorubicin (PDOX) is synthesized with a five-membered
pyrroline ring on the daunosamine sugar to act as a masked aldehyde and is, in vitro, more
than 500 times more potent against MCF-7 human breast adenocarcionoma than DOX
(Nagy, 1996). During intercalation, nitrogen from a DNA base pair acts as a nucleophile
to form an aminal adduct with the iminium carbon and then an adjacent base pair hydrogen
bonds to the C-9 hydroxyl to form an interstrand virtual cross-link (Figure 2.2) (Cullinane,
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1993). Alternatively, diacetate-protected analogs, with latent alkylating abilities, have
gained interest due to their enhanced stability, as they require enzymatic carboxylate
esterase activation before generating a reactive Schiff base (Cherif, 1992).

Figure 2.2
PDOX DNA cross-links. (A) During intercalation, a guanine base pair acts
as a nucleophile to form an aminal adduct with the iminium carbon. (B) Hydrogen bonding
with an adjacent base pair then completes the DNA virtual cross-link.
Based upon the reported success of modifying DOX, six analogs of DIDOX were
synthesized by attaching alkylating or latent alkylating moieties to the 3'-amine on the
daunosamine sugar (Figure 2.3). After synthesis of these new drugs, the in vitro
cytotoxicity was evaluated using a resazurin assay. It was thought that these groups would
allow for similar reactivity as seen with comparable DOX analogs, such that covalent
attachment to DNA would occur during intercalation to improve potency and reduce MDR
related cellular efflux (Streeter, 1986; Studenovsky, 2011).
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Figure 2.3
DIDOX analogs prepared and evaluated. DIDOX-a, DIDOX-b, and
DIDOX-c remove the free basic amine by forming rings. The structure of DIDOX-d,
DIDOX-e, and DIDOX-f all have a terminal di-acetate feature, requiring intracellular
enzymatic activation before cyclization. All analogs shown are in their free base form.
2.2 Results and Discussion
DIDOX analogs a-f have been structurally characterized and biologically evaluated
against seven tumor lines. Four of the six analogs have shown obvious cytotoxic
improvements compared with the parent DIDOX and several were equally as potent as
DOX. Not only did these analogs improve cytotoxicity, they also retained activity against
a MDR cell line, whereas, DIDOX and DOX became significantly less effective.
DIDOX-a and DIDOX-c were synthesized with the innate ability to form DNA
cross-links without metabolic activation as they contain a reactive masked aldehyde (Nagy,
1996). This differs from DIDOX-b, which forms these cross-links only after metabolic
activation (Lau, 1989). Three of these analogs (DIDOX-d,e,f) were synthesized as
diacetate-protected latent aldehydes that, as shown in Scheme 2.2, require enzymatic
carboxylate esterase activation to first form a geminal diol, which then readily condenses
to an aldehyde (Cherif, 1992). Further condensation with the daunosamine amine yields
the reactive cyclic moiety, which then forms covalent DNA adducts. Notably, the reactive
species of DIDOX-d and DIDOX-f resemble that of DIDOX-a and DIDOX-c, respectively,
while DIDOX-e forms a six-membered piperidono ring.
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Scheme 2.2 Activation of DIDOX latent aldehyde-analogs by carboxylate esterase.
(A) DIDOX-d was synthesized with a terminal diacetate, requiring activation to form a
reactive iminium. Activation is initiated when carboxylate esterase deprotects the diacetate
to form a germinal diol and then dehydration yields an aldehyde species that cyclizes to a
reactive pyrrolino iminium through condensation with the daunosamine amine. (B)
DIDOX-e and DIDOX-f follow analogous activation, with the reactive iminium being part
of a piperidono and 1,4-oxizinium moiety, respectively.
2.2.1 DIDOX-a
The synthesis of DIDOX-a used the protocol employed to prepare PDOX, which
involves condensing the 3'-amine with 4-iodobutyraldehyde (1c) to a Schiff base followed
by intramolecular nucleophilic displacement of the iodine (Nagy, 1996). The synthesis of
1c, prepared as shown in Scheme 2.3, first used a Finkelstein reaction to convert 4chlorobuteraldehyde-1,1-dimethyl acetal (1a) to the corresponding iodide. After
precipitation of the salts, using hexanes/ether, the pure product was obtained in 88% yield.
After substituting halogens, the dimethyl acetal was hydrolyzed in 65% yield to the
corresponding aldehyde using aqueous hydrochloric acid. This final iodo-aldehyde, 1c,
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was then used to synthesize DIDOX-a in yields that exceeded 80%. Optimal conditions
used 30 equivalents of 1c and ensured DIDOX was held at low concentrations (ca. 0.06
M). If the reaction was too concentrated, high molecular weight adducts were observed
with masses that were consistent with DIDOX dimerization. On the other hand, if the
DIDOX was too dilute the reaction would not go to completion. During purification, it was
necessary to treat the silica gel with triethylamine prior to loading DIDOX-a to avoid
significant decomposition. After purification, DIDOX-a was made into a TFA salt without
any significant loss of purity or yield.

Scheme 2.3 Synthesis of DIDOX-a. 1b was obtained using NaI to substitute the
chlorine of 1a with an iodine. Next, the dimethyl acetal becomes deprotected to an
aldehyde using aqueous HCl, which is then condensed with the 3'-amine of DIDOX to
produce DIDOX-a.
2.2.2 DIDOX-b
The synthesis to obtain DIDOX-b followed an established route derived from
previous literature procedures (Scheme 2.4) (Takahashi, 1982). First, both chlorines on 2a
were substituted for iodine, in 77% yield, and then DIDOX was treated with 20 equivalents
of 2b in DMF and DIPEA. The high concentration of diiodide was used to accelerate the
first SN2 substitution (e.g. slow intermolecular followed by quick intramolecular SN2), to
allow for a complete reaction in a reasonable amount of time. After stirring in the dark for
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two days and purified on silica, the morpholino DIDOX-b was obtained in 94% yield as a
free base, which was later converted to a TFA salt with no loss of yield or purity.

Scheme 2.4 Synthesis of DIDOX-b. Initially, substitution of both chlorines on 2a for
iodine occurred using NaI. Next, DIDOX-b was produced after the daunosamine 3'-amine
displaced both iodines by intermolecular then intramolecular SN2.
2.2.3 DIDOX-c
The synthesis of the cyanomorpholino group found in DIDOX-c required careful
consideration since the analogous DOX variant produced the desired product in only 14%
yield (Acton, 1981). Indeed, this compound was a by-product generated upon a NaBH3CN
reductive amination step en route to morpholino-DOX (Scheme 2.5). As shown, cyanide
from the reducing agent adds to the iminium carbon following the first condensation–but
before reduction–or after the second condensation. It was reported that the yield of this
reaction could not be improved, even when doping with additional cyanide from alternate
sources, such as NaCN.

Scheme 2.5 Cyanomorpholino through reductive alkylation. To begin, DOX will
first condense with 2,2'-oxybis[acetaldehyde]. Next, a cyanide will either react with the
iminium following a second condensation/reduction to form a cyanomorpholino or the
iminium is reduced first and a second condensation occurs before the nitrile forms.
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The first attempt to improve cyanomorpholino formation followed the synthetic
approach outlined in Scheme 2.6. This route was devised by modifying the work of
Tehrani, et al 2003. In their work, a relatively complex iminium salt was treated with KCN
to produce an -cyano tertiary amine in high yields. Applying this toward DIDOX-c
required synthesizing 2-(2-Iodoethoxy)acetaldehyde (3c), which was accomplished in two
steps from commercially available 3a. The first step substituted the chlorine for an iodine,
which proceeded without any problems and gave a good yield of 92%. The next step, DessMartin oxidation, was less efficient and the product was obtained in only a moderate 61%
yield. Alkylation of DIDOX with 3c, followed by treatment with trifluoroacetic acid
produced a reactive 1,4-oxizinium-DIDOX intermediate, as determined by LC-MS.
Isolation of this intermediate was unsuccessful since it rapidly decomposes during silica
gel purification. However, it was believed that purification would be successful after
forming the more stable cyanomorpholino by simply adding cyanide to the crude iminium
intermediate, in the form of either NaCN or BnMe3NCN. Unfortunately, neither cyanide
salt produced the desired product, and altering solvent (MeOH/EtOAc, DMF, DCM, and
ACN), reaction time, and reaction temperature yielded no evidence of successful
cyanomorpholino-DIDOX formation. In the end, this approach was not able to deliver the
desired result and other methods were investigated.
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NaHCO3

3a

80 oC, 18HR
92%

DMP

3b

RT
61%

3c

1) DIDOX, DIPEA
2) TFA

DIDOX-c

1,4-oxizinium-DIDOX

Scheme 2.6 Initial DIDOX-c synthetic attempt. Sodium iodide is used to replace the
3a chlorine and then 3b is oxidized using Dess-Martin periodinane. Cyclization of 3c onto
DIDOX occured by condensation of the aldehyde and 3'-amine, followed by intramolecular
Sn2 substitution to displace the iodine. Subsequent treatment with TFA forms a charged
1,4-oxizinium intermediate, which when treated with cyanide, produces the desired
cyanomorpholino.
The previous success and mild reaction conditions used during the formation of
DIDOX-b provided inspiration for a reagent that ultimately proved effective in creating
DIDOX-c (Scheme 2.7). This new reagent, 3f, was synthesized to mimic the structure of
the diiodide that was previously utilized, however, 3f would already contain the nitrile
required for preparation of the cyanomorpholino moiety. Thus, after two sequential
substitution reactions, the nitrile remains as part of the ring. To obtain 3f, previously
synthesized 3c was converted, in 81% yield, to the cyanohydrin, 3d, using aqueous NaCN
and acetic acid. The hydroxyl group was then formed into a mesylate leaving group, 3e, in
99% yield. Initially, attempts were made to alkylate DIDOX using 3e in hopes of producing
the cyanomorpholino product, but after many failed attempts it proved necessary to
substitute the mesylate for an iodine. This was achieved by heating the mesylate 3e and
NaI at 80 °C for 18 hours to obtain the product, 3f, in 89% yield. Strangely, the analogous
halogen substitutions to form 3b and 3f required two separate steps in order to obtain a
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final product in high yield. Initially, 3e had a chlorine in place of the iodine and both
mesylate and chlorine substitutions were attempted as a single step, however, a significant
amount of starting material remained, even after 48 hours with more than 4 equivalents of
NaI. Following alkylation of DIDOX with 3f, DIDOX-c was isolated as the main reaction
product in an exciting yield of 61% and 92% purity, which is more than four times greater
than previously published methods used to prepare the analogous cyanomorpholino-DOX.
Lastly, DIDOX-c was made into a TFA salt without significant loss of yield or purity.

Scheme 2.7 Synthesis of DIDOX-c. The previously synthesized aldehyde, 3c, was
transformed into a cyanohydrin using aqueous sodium cyanide and then the hydroxyl was
made into a mesylate leaving group. Sodium iodide was used again to replace the mesylate.
Finally, 3f is used to synthesize DIDOX-c by double nucleophilic substitution.
2.2.4 DIDOX-d and DIDOX-e
DIDOX-d and DIDOX-e were designed to be latent aldehydes comparable to the
DOX analogs developed by Cherif et al. and Farquhar et al. The analogs, with their
previously described latent aldehydes, were synthesized using the route depicted in
Scheme 2.8. The chemistry to obtain each of the appropriate reagents, 4d and 5d, followed
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the same scheme and were produced with adequate yields. The first reaction involved DessMartin oxidation of either 4-penten-1-ol or 5-hepten-1-ol, both of which are commercially
available. The newly formed aldehydes were treated with acetic anhydride and catalytic
InCl3 (0.05 equivalents) to produce the di-acetates 4c and 5c in yields of 89% and 43%,
respectively, over two steps. Lastly, olefin oxidative cleavage was then performed
successfully to obtain 4d and 5d using sodium periodate and catalytic RuCl3 (0.035
equivalents) in greater than 40% yield (Yang, 2001).

Scheme 2.8 Synthesis of DIDOX-d and DIDOX-e. The synthetic steps to reach 4d and
5d are identical and only starting materials, 4a and 5a, differ in the length of one methylene.
The alcohol is oxidized using Dess-Martin to produce an aldehyde. It is then reacted with
acetic anhydride to yield di-acetates 4c and 5c. The final aldehydes generated upon
oxidative cleavage of the terminal olefin were used to produce DIDOX-d or DIDOX-e in
45% and 50% yield, respectively.
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Once 4d and 5d were prepared, a reductive activation sequence, proven successful
with DOX, was employed. Specifically, DIDOX was treated with 5 equivalents of either
aldehyde, 4d or 5d, and the reducing agent NaBH3CN in a 2:1 ACN/H2O mixture at room
temperature for 60 minutes. While these conditions provided success with DOX, no
isolatable DIDOX products were generated.
The desired products were eventually synthesized by using a larger excess of 4d or
5d (8 equivalents) and altering the solvent to hexafluoroisopropanol (Govindan, 2014).
Also, the reducing agent had to be changed to NaHB(OAc)3, because NaBH3CN was
incompatible with this new protonated solvent. The reaction was allowed to proceed for 10
minutes before being directly applied to silica gel for purification. When using DOX as a
model system, these conditions generated the desired products in yields approaching 90%.
However, when applied to the iminoquinone-containing DIDOX, the products were
obtained in yields closer to 50%, after formation of the TFA salt. This result suggests that
further optimization is warranted, by variation in solvent, temperature, reducing agent,
reaction time, etc.
2.2.5 DIDOX-f
After successful completion of the pro-drugs DIDOX-d and DIDOX-e, attention
was shifted to a pro-drug analog of DIDOX-c. The initial attempt to form this DIDOX
analog followed the route depicted in Scheme 2.9, which was reported to be successful
with DOX (Farquhar, 1998). However, when applied to DIDOX, no isolatable product
could be obtained. Upon monitoring the reaction via LC-MS, two main products with
nearly identical elution times were observed in the chromatogram. Based on the mass to
charge ratio, one appeared to be the desired product, whereas, the other had a mass of
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731.35 amu and, unfortunately, could not be structurally determined. All attempts at silica
gel purification, using numerous solvent systems, were unsuccessful at providing a purified
product.

Scheme 2.9 PromorpholinoDOX by reductive alkylation. Formation of product
occurred by condensation of DOX and [(2,2-diacetoxyethyl)oxy]-acetaldehyde ether
followed by STAB reduction.
A second approach to prepare DIDOX-f used 2-(2-iodoethoxy)ethylidene diacetate
(6d, Scheme 2.10) and was marginally successful. The synthesis of 6d involved conversion
of the previously prepared 3c to the diacetate 6d, which was then combined with DIDOX
to afford the desired product. As with the other pro-drug analogs, the InCl3/Ac2O approach
for preparing the diacetate was attempted, but was abandoned after NMR data showed no
sign of product formation. However, switching to a stronger Lewis acid, FeCl 3, generated
6d in 65% yield (Kockhar, 1983). Using this iodide reagent, the pro-drug, DIDOX-f, was
formed via a simple nucleophilic substitution over the course of 72 hours.
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Scheme 2.10 Synthesis of DIDOX-f. The aldehyde, 3c, was obtained via previously
described methods. Iron (III) chloride and acetic anhydride reacted with 3c for 45 minutes,
while chilled on ice, to produce 6d. The iodide, 6d, was stirred with DIDOX for 72 hours
at room temperature to generate DIDOX-f.
While the synthesis of DIDOX-f was successful, purification proved problematic
as silica gel chromatography resulted in rapid decomposition. Unfortunately, if the silica
was neutralized by treatment with triethylamine, the product and all of the impurities eluted
together. Furthermore, attempts to obtain pure product using reverse-phase silica were not
successful. Ultimately, a series of purifications were required to obtain a pure analog. The
initial purification involved slowly eluting using CHCl3/IPA and collecting semi-pure
fractions. Next, a second column using CHCl3/MeOH was performed and the exposure to
silica gel was minimized to prevent serious degradation. The inefficient purification
provided the analog in only 14% yield, after converting to a TFA salt, however, with a
purity of greater than 90%. Given that the LC chromatogram demonstrated the crude
product consisted of roughly 50% DIDOX-f, further optimization of purification
techniques will improve this abysmal result.
2.2.6 In Vitro Cytotoxicity Results of DIDOX Analogs
To evaluate the anticancer activity of the DIDOX analogs, several different cell
lines were employed in cytotoxicity assays. Specifically, all the analogs, DIDOX, and
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DOX were subjected to a series of resazurin reduction assays—results of which are shown
in Table 2.1—to compare antiproliferative activity (Mallory, 2015). This assay followed
the reduction of non-fluorescent blue resazurin to fluorescent pink resorufin, which only
occurs in healthy and metabolically active cells. The cell lines used include DOX-resistant
MES-SA/MX2 uterine sarcoma and non-resistant MES-SA uterine sarcoma, SW-872
liposarcoma, RDCCL136 rhabdomyosarcoma, HT1080 and HT1080-luc2 fibrosarcoma,
and CT-26 mouse colon carcinoma. As expected, the data clearly demonstrates that
conversion of DOX to DIDOX reduces efficacy across all cancer lines—typically by
orders-of-magnitude—and, for the most part, functionalization of the 3'-amine generally
returns potency back to similar levels displayed by DOX. These cytotoxicity results
provide an initial opportunity to draw conclusions regarding the structural features that are
important for anticancer activity.
Table 2.1
In vitro activity of DOX, DIDOX, and DIDOX-analogs against
sarcoma and carcinoma cell lines.a

a

The IC50 values were obtained and shown as the mean (±SEM) of at least n = 3, unless marked with an asterisk, indicating
preliminary values (n < 3). IP = in progress. Cytotoxicity data was collected by Phil Moon, LJ McKenzie, and Tyler
Smith.

60
While most DIDOX analogs increased cytotoxicity, the results showed that
DIDOX-b produced IC50 values ranging from 55 µM to 84.8 µM, considerably less potent
than the parent DIDOX. The lack of reactivity is presumably due to the morpholino ring
requiring biotransformation from hepatic oxidases in order to become active (Lau, 1989).
Such enzymatic activation would likely occur by hydroxylation of either nitrogen αcarbons on the morpholino ring that would offer analogous cytotoxic properties as the
cyanomorpholino substituent. As such, these in vitro experiments may not suitably
represent whole animal systems.
When comparing DIDOX-d and DIDOX-e, the only difference is that, respectively,
one forms a five-membered ring and the other a six-membered ring after enzymatic
activation. At first glance, the addition of one carbon may seem insignificant, but the
results, so far, clearly show that the five-membered ring is consistently orders-ofmagnitude more cytotoxic. For instance, DIDOX-d has an IC50 of 0.37 µM for SW-872
liposarcoma, while DIDOX-e, having an IC50 of 63.24 µM, is more than 150 times less
potent. Although it is not entirely known why, the drastic change in potency may be
attributed to the increase in steric hindrance a six-membered ring contains. This
explanation becomes more reasonable when realizing that a five-membered ring is nearly
planar, whereas, a six-membered ring forms a bulky chair conformation. It’s quite possible
that this expanded structure forces the iminium carbon further from DNA base pairs,
reducing its ability to covalently bind (Nagy, 1996).
Although the six-membered ring of DIDOX-e hinders its cytotoxic ability, the six
membered rings of DIDOX-c and DIDOX-f analogs are vastly more potent. Preliminary
results show that DIDOX-c and DIDOX-f are comparably cytotoxic with IC50 values as

61
low as 0.32 µM and 0.15 µM, respectively. The difference stems from these two analogs
containing an oxygen at the 4-position, which produces less steric hindrance compared to
the methylene of DIDOX-e. Also, hydrogen bonding from this oxygen may be important
in bringing this moiety into close proximity or correct orientation to facilitate DNA
binding.
The only analog with an inherently reactive site is DIDOX-a, the other DIDOX
analogs require some form of activation. The importance behind this observation can be
realized when comparing DIDOX-a to its pro-drug DIDOX-d. So far, the cytotoxicity of
the protected form is up to six times more potent than the continuously active pyrrolino,
however this data is preliminary and warrants further investigation. Due to the fact that
DIDOX-a does not require enzymatic activation, it is potentially available to react with
surrounding proteins instead of the DNA target, thus decreasing its cytotoxicity.
Additional benefits from functionalization of the 3'-amine appears to include lower
susceptibility to MDR and PGP-mediated efflux. Against the MES-SA cell lines, DOX and
DIDOX had IC50 values of 0.69 µM and 10.6 µM, respectively. Against the resistant MESSA/MX2 cell lines, the IC50 values were up to 20-fold greater. However, as expected, the
3'-amine substituted DIDOX analogs displayed similar activity against the set of resistant
and non-resistant cell lines.
2.3 Conclusion
Six analogs of DIDOX were synthesized by functionalization of the 3'-amine to
improve the ability to form DNA interstrand cross-links and were evaluated for cytotoxic
improvement, as well as for the susceptibility of MDR. Three of the analogs were
developed in an already active form and three were isolated as protected latent aldehydes
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to improve stability. The synthesis of DIDOX-a,b,d,e analogs used reaction schemes that
had been reported to successfully prepare comparable DOX derivatives. However, new
synthetic routes were required to isolate DIDOX-c and DIDOX-f. To acquire DIDOX-c, a
novel reagent, 2-iodo-3-(2-iodoethoxy)propanenitrile, was prepared and used to alkylate
DIDOX through two subsequent nucleophilic substitutions (intermolecular then
intramolecular) to form a cyanomorpholino ring in yields greater than 60%. Furthermore,
DIDOX-f was produced by single nucleophilic substitution using the newly synthesized
reagent, 2-(2-iodoethoxy)ethylidene diacetate.
Results from the resazurin reduction assay determined that most of the
modifications allowed DIDOX to regain potency back to comparable levels seen with
DOX. This was demonstrated with only a few exceptions, such as in the MES-SA cell line
when comparing DIDOX with DIDOX-b, which can be attributed to the absence of
oxidases required for morpholino biotransformation. In addition, DIDOX-e consistently
performed inadequately compared to other analogs due to its activated form being a more
sterically hindered six-membered piperidono ring. From these results, it can be determined
that the modification of the 3'-amine appears to produce more cytotoxic anticancer agents,
particularly when the modifications include a reactive Schiff base or masked aldehyde. As
expected, these modifications appear, at least initially, to overcome MDR as a result of
encumbering the free basic amine, which is essential for PGP-mediated drug efflux. Future
work will focus on improving the yields of the DIDOX analogs by trying different reaction
conditions (i.e. solvents, reagents, temperature, concentration, etc.) and optimization of the
purification process. Notably, optimization of purification would drastically benefit the
synthesis of DIDOX-f, since HPLC analysis suggested it was produced in high yield prior
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to purification, but degradation during silica gel chromatography allowed for only 14%
yield. In conclusion, the cytotoxicity data, so far, supports the premise that these
modifications do in fact produce potent DIDOX analogs that can overcome MDR that will
potentially remain non-cardiotoxic.
2.4 Materials and Methods
2.4.1 Materials and Reagents
DIDOX was supplied by Gem Pharmaceuticals, LLC. Doxorubicin hydrochloride
was purchased from Advanced ChemBlocks, Inc. Ethylene glycol mono-2-chloroethyl
ether and 4-chlorobuteraldehyde dimethyl acetal were purchased from TCI. Sodium iodide
and indium(III) chloride came from Strem Chemicals Inc. Both sodium bicarbonate and
hydrochloric acid were supplied from VWR Analytical. Chemicals purchased from
Oakwood Chemical include Dess-Martin periodinane, 1,1,1,3,3,3-hexafluoro-2-propanol,
and ruthenium chloride. Sodium cyanide, DIPEA, trifluoroacetic acid, and sodium
thiosulfate were purchased from Alfa Aesar. Methane sulfonyl chloride, acetic anhydride,
and sodium triacetoxyborohydride were obtained from Acros Chemical. 5-Hexene-1-ol,
sodium metaperiodate, and 4-pentene-1-ol were purchased from Beantown Chemical.
Acetic acid was purchased from EMD. Triethylamine and all solvents were purchased from
Fisher Scientific unless otherwise specified.
For cytotoxicity assays, DOX, DIDOX, and DIDOX analogs were all diluted to 30
mM stock solutions in anhydrous DMSO (obtained from Sigma-Aldrich) and stored at -80
°C. All media and components of media were obtained from Thermo Fisher Scientific if
not stated otherwise.
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2.4.2 Equipment
NMR data was acquired using either 600MHz Bruker Avance III 600 coupled with
Bruker Ultrashield 600 Plus or 300MHz Bruker Ultrashield 300 coupled with Bruker
Avance III 300. HPLC chromatography was performed using Agilent 1100 series equipped
with 50x4.6 mm Hypersil Gold Phenyl column having 5 µm pore size. Coupled with the
HPLC was a Bruker Daltonics HCT ultra ETD II ion trap mass spectrometer. A Bruker
Daltonics maXis quadrupole time-of-flight was used for high resolution mass spectrometry
analysis during DIDOX analog characterization.
2.4.3 Cell Cultures
The following cell lines were purchased from American Type Culture Collection:
HT1080, RDCCL, SW-872, MES-SA, and MES-SA/MX2. HT1080-luc2 was ordered
from Perkin Elmer. Cells were incubated at 37 °C in a humidified atmosphere containing
5% CO2. Dulbecco’s Modified Eagle Medium—supplemented with 10% (v/v) fetal
bovine serum and 1% penicillin/streptomycin—was used to culture RDCCL136, SW872, MES-SA, and MES-SA/MX2. MES-SA/MX2 was grown under 1 μM DOX stress.
Minimum Essential Medium—with 10% fetal bovine serum and 1%
penicillin/streptomycin—was used to culture both HT1080 and HT1080-luc2.
2.4.4 In Vitro Assays
A resazurin reduction assay was used to determine the cytotoxicity of DOX,
DIDOX, and DIDOX analogs against an array of cancer lines (Mallory, 2015). Cells were
washed with 1x PBS three times and suspended in trypsin-EDTA while incubating at 37
°C for five minutes. After suspension was achieved, the cells were placed into a centrifuge
at 1200 x g for five minutes to form a small pellet. The supernatant was discarded and the
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cells were resuspended into their respective media to produce a concentration between
25,000-40,000 cells/mL. These cells were then seeded in a 96-well plate where each well
contained between 5,000-8,000 cells. The 96-well plate was then allowed to incubate in a
humidified 5% CO2 atmosphere at 37 °C overnight. After incubating, the media was
removed from the wells and discarded. The wells were replenished with 180 μL fresh
media and 20 μL drug at the appropriate concentration. The cell-drug combination was
allowed to incubate for 48 hours and then 20 μL 0.1% (w/v) resazurin was added to each
well and incubated for an additional 24 hours. Fluorescent data was then collected using a
BioTek Synergy HT Multi-detection microplate reader and graphed using GraphPad Prism
as percent viability versus drug concentration.
2.4.5 Experimental
4-Iodobuteraldehyde dimethyl acetal (1b)
4-Chlorobuteraldehyde dimethyl acetal (2.5 ml, 17.0 mmol) was made to be 0.25 M in dry
acetone. NaI (5.1070 g, 34.0 mmol, 2 eq) and NaHCO3 (0.4285 g, 5.1mmol, 0.3 eq) were
then added and reaction was placed under nitrogen. It was allowed to reflux at 80 ºC for 24
h before removing from heat and allowing solution to cool to RT. The acetone was then
removed in vacuo and 35 mL Et2O was added and stirred for 10 min. The precipitates were
removed via filtration and discarded. The solvent was then evaporated leaving 3.6611 g
clear oil (88% yield). The NMR spectral data matched that previously reported (Wu, 1994).
4-Iodobutanal (1c)
4-Iodobuteraldehyde dimethyl acetal (3.6611 g, 15.0 mmol) was dissolved in 150 mL THF
before adding 500 mL H2O/HCl (20:1, v/v). The reaction was monitored by TLC using
hexanes/Et2O (9:1, v/v) and potassium permanganate staining. When reaction was
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completed, it was added to a separatory funnel and crude product extracted using 100mL
DCM x3. This was then dried using sodium sulfate, filtered, and solvent evaporated. The
crude oil was purified on silica gel using hexanes/Et2O (3:1, v/v). All fractions containing
product (Rf = 0.17) were combined, yielding 1.9176 g of pale yellow oil (65% yield). The
NMR spectral data matched that previously reported (Studenovsky, 2011)
Bis(2-Iodoethyl) ether (2b)
Bis(2-iodoethyl) ether (1.3171 g, 9.21 mmol) was made to be 0.2 M in dry acetone before
NaI (5.5219 g, 36.8 mmol, 4 eq) and NaHCO3 (0.4642 g, 5.53 mmol, 0.6 eq) were added.
This was allowed to react under reflux at 80 ºC for 24 h under a nitrogen atmosphere before
removing from heat. After cooling to RT, 40 mL of Et2O was added and mixed for 10 min
before precipitates were removed by filtration. Solution was then dried in vacuo and 50 mL
Et2O was added and mixed for 10 minutes and the additional precipitates were removed by
filtration. After drying, the final production was obtained as a yellow oil (3.0017 g) in 77%
yield. 1H NMR (CDCl3 with 0.03% v/v TMS, 300 MHz) : 3.77 (t, 4H, J = 6.8 Hz), 3.27
(t, 4H, J = 6.8 Hz)
2-(2-Iodoethoxy)ethanol (3b)
Ethylene glycol mono-2-chloroethyl ether (0.500 mL, 4.74 mmol) was dissolved in 24 mL
dry acetone before NaI (1.5589 g, 10.4 mmol, 2.2 eq) and NaHCO3 (0.1193 g, 1.42 mmol,
0.3 eq) were added to the solution. It was allowed to reflux at 85 °C for 24 h and then
diluted to 0.05 M using EtOAc and washed five times using 15 mL water. The organic
solution was dried using sodium sulfate, followed by filtration. The solvent was evaporated
in vacuo to deliver 0.9420 g pure product (92% yield) as a colorless oil. NMR spectral data
matches that previously reported (Phillips, 2008)

67
2-(2-Iodoethoxy)acetaldehyde (3c)
2-(2-Iodoethoxy)ethanol (3.0675 g, 14.2 mmol,) was dissolved in 40 mL DCM and then
Dess-Martin (9.0342 g, 21.3 mmol, 1.5 eq) was added. The solution was developed in
EtOAc/Hexanes (3:2, v/v) on TLC. Following chromatography, the plate was stained using
potassium permanganate to resolve a bright yellow spot with Rf = 0.35 for SM and Rf =
0.53 for product. Once SM was no longer present on TLC (3.5 h), the reaction was
quenched using 100 mL 15% Na2S2O3/5% NaHCO3. Crude product was then extracted
using 50 ml DCM x3, dried using sodium sulfate, and filtered. After evaporation of solvent,
the crude oil was applied to silica gel and eluted using EtOAc/Hexanes (1:1, v/v). Fractions
containing product – determined using TLC – were combined and condensed, providing
1.8401 g of pure colorless oil (61% yield). 1H NMR (CDCl3 with 0.03% v/v TMS, 300
MHz) : 9.72 (s, 1H), 4.17 (s, 2H), 3.84 (t, 2H, J = 6.7 Hz), 3.31 (t, 2H, J = 6.7)
2-hydroxy-3-(2-iodoethoxy)propanenitrile (3d)
2-(2-Iodoethoxy)acetaldehyde (1.2028 g, 5.62 mmol) was made to be 2.9 M in AcOH (1.9
mL) and NaCN (0.8264 g, 16.9 mmol, 3 eq) was made to be 0.9 M in water (19 mL). Both
solutions were allowed to chill to ~0 ºC before the NaCN solution was added to the
aldehyde via cannula and allowed to react overnight (16 h) at 5 ºC. It was quench by adding
to 150 mL saturated aqueous NaHCO3 and extracting crude product using 50 mL DCM x4.
The organic solution was then dried using sodium sulfate, filtered, and solvent evaporated
in vacuo. The desired product had an Rf of 0.60 on TLC using EtOAc/Hexanes (3:2, v/v)
and required staining using potassium permanganate. The crude oil was applied to silica
gel and eluted using Hexanes/EtOAc (2:1, v/v) resulting in 1.1005 g clear oil (81% yield).
1

H NMR (CDCl3 with 0.03% v/v TMS, 300 MHz) : 4.61 (dt, 1H, J = 8.3 Hz, 4.1 Hz),

68
3.96-3.77 (m, 4H), 3.31 (t, 2H, J = 6.4 Hz), 3.10 (dd, 1H, J = 30.2 Hz, 8.3 Hz). 13C NMR
(CDCl3 with 0.03% v/v TMS, 600 MHz) :117.8, 72.1, 71.2, 60.8, 2.1.
3-(2-iodoethoxy)-2-(methylsulfonyl)propanenitrile (3e)
2-hydroxy-3-(2-iodoethoxy)propanenitrile (1.0851 g, 4.50 mmol) was dissolved in 3 mL
anhydrous DCM while methane sulfonyl chloride (418 L, 5.40 mmol, 1.2 eq) was
dissolved in 27 mL anhydrous DCM, both chilled to 0 ºC. The sulfonyl chloride solution
was added to the cyanohydrin followed by triethylamine (1.25 mL, 9.00 mmol, 2 eq) and
reacted for 30 min at 0 ºC and then allowed to warm to RT. The reaction was monitored
via TLC using EtOAC/Hexanes (3:2, v/v) and stained with potassium permanganate.
Product had Rf = 0.64. When SM had disappeared – shown by TLC – it was added to 150
mL water and crude product extracted using 50 mL DCM x3, then dried using sodium
sulfate, and filtered. Solvent was removed in vacuo and crude oil was applied to silica gel.
Purification using EtOAc/Hexanes (1:1, v/v) yielded 1.4138 g of clear oil (99% yield). 1H
NMR (CDCl3 with 0.03% v/v TMS, 600 MHz) : 5.33 (dd, 1H, J = 6.2 Hz, 4.8 Hz), 3.973.83 (m, 4H), 3.27 (t, 2H, J = 6.6 Hz), 3.23 (s, 3H, CH3). 13C NMR (CDCl3 with 0.03% v/v
TMS, 600 MHz) : 113.9, 72.6, 69.6, 65.4, 39.2, 1.1.
2-iodo-3-(2-iodoethoxy)propanenitrile (3f)
3-(2-iodoethoxy)-2-(methylsulfonyl)propanenitrile (1.2892 g, 4.04 mmol) was dissolved
in 16 mL anhydrous acetone. NaI (1.2111 g, 8.08 mmol, 2 eq) and NaHCO3 (0.1017 g,
1.21 mmol, 0.3 eq) were then added and reaction was refluxed at 80 ºC for 18 h. This was
monitored via TLC using EtOAc/Hexanes (3:2, v/v) and staining with potassium
permanganate, product Rf = 0.70. After SM had all been used, the solution was cooled to
RT and the 5 mL of Et2O was added and precipitates were removed by filtration and washed
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with 10 mL Et2O x5. Excess solvent was evaporated and crude product was added to 150
mL water and extract using 50 mL DCM x4. It was then dried using sodium sulfate, filtered,
and solvent removed. It was then applied to silica gel and purified using EtOAc/Hexanes
(1:1, v/v). Fractions containing product were combined and solvent evaporated. 1.2548 g
of clear oil was obtained (89% yield) with a density of 1.8 g/mL. 1H NMR (CDCl3 with
0.03% v/v TMS, 300 MHz) : 4.33 (dd, 1H, J = 7.7 Hz, 6.8 Hz), 3.93-3.83 (m, 4H), 3.28
(dt, 2H, J = 6.8 Hz, 0.9 Hz). 13C NMR (CDCl3 with 0.03% v/v TMS, 600 MHz) : 117.7,
72.9, 72.3, 1.3, -6.2.
5-Hexene-1,1-Diacetate (5c)
5-Hexene-1-ol (1.20 mL, 10 mmol) was dissolved in 30 mL DCM and chilled to between
0-5 ºC on ice. Dess-Martin periodinane (5.0897 g, 12.0 mmol, 1.2 eq) was then added and
stirred on ice for 5 min. It was then allowed to warm to RT. Reaction progress was
monitored by TLC using hexanes/Et2O (1:1, v/v) followed by potassium permanganate
staining. When starting material had completely reacted, 100 mL aqueous 15% sodium
thiosulfate/5% sodium bicarbonate was added and allowed to stir for 10 min to quench.
Crude product was then extracted using 30 mL DCM x3, dried using sodium sulfate, and
filtered. The solvent was then evaporated to produce crude 5-hexene-1-al. This was then
diluted with 30 mL ice-cold DCM and InCl3 (0.1106 g, 0.5 mmol, 0.05 eq) was added and
allowed to thoroughly mix for 5 minutes before Ac2O (1.42 mL, 15.0 mmol, 1.5 eq) was
added. This was monitored by TLC using hexanes/Et2O (8:1, v/v) followed by potassium
permanganate staining. Reaction was complete after 48 h and quenched using 20 mL
aqueous 25% sodium acetate and then added to 70 mL brine. Product was extracted using
25 mL DCM x4, then dried using sodium sulfate, and filtered. After solvent was
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evaporated, it was loaded onto silica gel and purified using hexanes/Et2O (2:1, v/v). All
fractions containing product (Rf of 0.14) were combined to give 0.8655 g (43% yield) clear
oil. The NMR spectral data matched that previously reported (Cherif, 1992)
4-Pentene-1,1-diacetate (4c)
Product obtained using same procedures as 5-Hexene-1,1-Diacetate. Final product Rf was
found to be 0.26. Yield was 89% over first two steps. The NMR spectral data matched that
previously reported (Cherif, 1992)
5-Oxopentane-1,1-diacetate (5d)
5-Hexene-1,1-diacetate (0.7117 g, 3.55 mmol) and RuCl3 (25.8 mg, 0.124 mmol, 0.035 eq)
were made to be 0.1 M in ACN/H2O (6:1, v/v) and mixed for 3-4 min. Sodium periodate
(1.5186 g, 7.10 mmol, 2 eq) was then slowly added over 5 minutes. This was monitored by
TLC using EtOAc/hexanes (3:2, v/v) stained with potassium permanganate. Reaction was
complete, shown by TLC, after 3 h. It was then added to a separatory funnel along with 40
mL saturated aqueous sodium thiosulfate and vigorously shaken. The top organic layer was
removed and set aside. Product was extracted from the aqueous layer using 25 mL EtOAc
x3. All the organic layers were then combined and washed with 40 mL H2O followed by
an additional wash using 40 mL brine. It was then dried using sodium sulfate, filtered, and
solvent removed in vacuo. The crude oil was loaded onto silica gel and purified using
EtOAc/hexanes (1:1, v/v). All fractions containing product (Rf of 0.12) were combined,
yielding 0.3189 g (45% yield) clear oil. The NMR spectral data matched that previously
reported (Cherif, 1992)
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4-Oxobutane-1,1-diacetate (4d)
Product obtained using same procedures as 5-Oxopentane-1,1-diacetate. Final product Rf
was found to be 0.49. Yield was 47%. The NMR spectral data matched that previously
reported (Cherif, 1992)
2-(2-Iodoethoxy) ethylidene diacetate (6d)
2-(2-Iodoethoxy)acetaldehyde (1.3704 g, 6.40 mmol) was chilled to 0 ºC and dissolved in
2.1 mL ice-cold acetic anhydride. This was allowed to react on ice for 15 min and then
FeCl3 (31.2 mg, 0.192 mmol, 0.03 eq) was added and reaction proceeded an additional 20
min while still on ice. It was then added directly onto silica gel for purification using
Hexanes/Et2O (2:1, v/v). TLC was performed using Hexanes/Et2O (8:3, v/v) followed by
potassium permanganate staining. Product Rf was 0.19. All pure fractions were collected
and combined to give 1.3094 g clear oil (65% yield). 1H NMR (CDCl3 with 0.03% v/v
TMS, 600 MHz)  6.91 (t, 1H, J = 4.9 Hz), 3.79 (t, 2H, J = 6.8 Hz), 3.69 (d, 2H, J = 4.9
Hz), 3.24 (t, 2H, J = 6.8 Hz), 2.11 (s, 6H).

13

C NMR (CDCl3 with 0.03% v/v TMS, 600

MHz) : 168.8, 87.5, 72.3, 69.7, 20.8, 2.1
DIDOX-a
DIDOX HCl (93.5 mg, 0.165 mmol) was made to be 0.1 M DMF and 4-iodobutanal
(0.9830 g, 4.96 mmol, 30 eq) was made to be 0.06 M in DCM containing DIPEA (172 L,
0.990 mmol, 6 eq). DCM solution was added to the dissolved DIDOX over 5 min. Reaction
was monitored via LC-MS. The reaction was complete after 5 h and 3 mL 5% TFA in
MeOH was added. The solution was then condensed to 5 mL and recrystallized using 25
mL Et2O/hexanes (4:1, v/v). The purple precipitate was then loaded onto silica gel (treated
with 0.5% triethylamine) and purified using CHCl3/MeOH (10:1, v/v). Fractions
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containing product were combined and 3 mL 10% TFA in MeOH was added and solution
condensed to 5 mL. It was then recrystallized using 20 mL Et2O/hexanes (4:1, v/v). The
solid was then placed under high vacuum for one h (<150 mTorr). The final product was
obtained in 80% yield (91.6 mg) as a purple TFA salt with purity of >90%. Molecular ion
(M+H+) calculated for C31H37N2O9+: 581.2494 amu; found m/z = 581.2489 amu, error = 0.86 ppm.
DIDOX-b
DIDOX HCl (43.0 mg, 0.0761 mmol) was dissolved in 2.0 mL DMF and then bis(2iodoethyl) ether (495.1 mg, 1.52 mmol, 20 eq) was added and stirred for 5 min before
DIPEA (79.5 µL, 0.457 mmol, 6 eq) was added. The reaction progress was monitored by
HPLC. Starting DIDOX had completely reacted after two days prompting the addition of
18 mL Et2O/hexanes (2:1, v/v) to recrystallize crude product. The purple solid was purified
using silica gel packed into a 1 X 15 cm column using 200 mL 20:1 CHCl 3/MeOH then
200 mL 10:1 CHCl3/MeOH. Fractions containing product were collected and solvent was
removed. The solid was collected and placed under high vacuum for 45 min (<150 mTorr).
Final product was obtained as a purple solid (42.7 mg) in 93.6% yield and 96% purity.
Molecular ion (M+H+) calculated for C31H39N2O10+: 599.2600 amu; found m/z = 599.2619
amu, error = 3.17 ppm.
DIDOX-c
DIDOX HCl salt (48.6 mg, 0.0860 mmol) was made to be 0.08 M in DMF that already
contained 2-iodo-3-(2-iodoethoxy)propanenitrile (754.5 mg, 2.15 mmol, 25 eq) followed
by the addition of DIPEA (90 L, 0.516 mmol, 6 eq). The reaction completed after 50 h as
determined via LC-MS. At this point 25 mL Et2O/Hexanes (4:1, v/v) was added and
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precipitate was collected. It was then dissolved in 2 mL 1:1 MeOH/DCM (v/v) and
recrystallized a second time using 25 mL Et2O/Hexanes (4:1, v/v). The crude solid was
then purified on a column (3 X 15 cm) packed with silica gel. The mobile phase consisted
of CHCl3/MeOH (10:1, v/v). Fractions containing product were collected and solvent
removed in vacuo. The pure product was then placed under high-vacuum for 60 min (<150
mTorr). A purple DIDOX-c solid (32.9 mg) was obtained in free base form with a yield of
61% and purity of 92%. A 10.9 mg sample of free base DIDOX-c was dissolved in 1 mL
of 1:1 MeOH/DCM (v/v) containing 5% TFA and mixed for 5 min before 12 mL
Et2O/Hexanes (4:1, v/v) was added. The precipitate was collected and dried under highvacuum ((<150 mTorr) for 45 min. 12.9 mg of the final purple solid was obtained as a TFA
salt in 100% yield with a purity of 90%. Molecular ion (M+H+) calculated for
C32H38N3O10+: 624.2552 amu; found m/z = 624.2596 amu, error = 7.05 ppm.
DIDOX-d
DIDOX HCl (46.6 mg, 0.0825 mmol) was made to be 0.02 M in 1,1,1,3,3,3-hexafluoro-2propanol containing 4-oxobutane-1,1-diacetate (0.1242 g, 0.660 mmol, 8 eq) and then
DIPEA (86 L, 0.495 mmol, 6 eq) was added. This was allowed to stir for 3 min before
sodium triacetoxyborohydride was added and reacted for 10 min. It was then directly
loaded onto a column (2 X 15 cm) packed with silica gel. It was purified using 300 mL
CHCl3/MeOH (20:1, v/v), followed by 250 mL CHCl3/MeOH (10:1, v/v), and finally with
200 mL CHCl3/MeOH (4:1, v/v). Fractions containing product (determined by LC-MS)
were combined and evaporated to dryness. The purple solid was then dissolved in 1 mL
3% TFA in MeOH and stirred for 5 min before recrystallizing using 15 mL Et2O/hexanes
(5:1, v/v). The solid was then placed under high vacuum for one h (<150 mTorr). The final
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product was obtained in 45% yield (30.0 mg) as a purple TFA salt with purity of >95%.
Molecular ion (M+H+) calculated for C35H45N2O13+: 701.2917 amu; found m/z = 701.3009
amu, error = 13.1 ppm.
DIDOX-e
DIDOX HCl (44.6 mg, 0.0789 mmol) was made to be 0.03 M in 1,1,1,3,3,3-hexafluoro-2propanol containing 5-oxopentane-1,1-diacetate (0.1594 g, 0.789 mmol, 10 eq) followed
by the addition of DIPEA (82 L, 0.473 mmol, 6 eq) and allowed to stir for 2 min. Sodium
triacetoxyborohydride (25.0 mg, .0118 mmol, 1.5 eq) was added and reacted for 10 min
before being loaded directly onto a column (2 X 15 cm) packed with silica gel. It was
purified using 300 mL CHCl3/MeOH (20:1, v/v), followed by 250 mL CHCl3/MeOH (10:1,
v/v), and finally with 200 mL CHCl3/MeOH (4:1, v/v). Fractions containing product
(determined by LC-MS) were combined and evaporated to dryness. The purple solid was
then dissolved in 1 mL 3% TFA in MeOH and stirred for 5 min before recrystallizing using
15 mL Et2O/hexanes (5:1, v/v). The solid was then placed under high vacuum for one h
(<150 mTorr). The final product was obtained in 50% yield (32.8 mg) as a purple TFA salt
with purity of >95%. Molecular ion (M+H+) calculated for C36H47N2O13+: 715.3073 amu;
found m/z = 715.3059 amu, error = -1.96 ppm.
DIDOX-f
DIDOX HCl (20.9 mg, 0.0370 mmol) was dissolved in 2 mL DMF containing 2-(2iodoethoxy) ethylidene diacetate (0.2339 g, 0.740 mmol, 20 eq) and DIPEA (39 L, 0.222
mmol, 6 eq) was added via syringe. Reaction was monitored via LC-MS. After 72 h, the
solution was added to 150 mL H2O and extracted using 25 mL DCM x4. It was then dried
using sodium sulfate, filtered, and solvent evaporated. The purple solid was then dissolved
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in 1 mL DCM/MeOH (1:1, v/v) and recrystallized using 20 mL Et2O/hexanes (3:1, v/v).
The solid precipitate was loaded onto silica gel and purified using CHCl3/IPA (2:1, v/v).
Fractions containing product were collected and solvent evaporated. Product at this point
was less than 90% pure so an additional purification was performed on silica gel using
CHCl3/MeOH (4:1, v/v). Fractions containing product were combined and solvent
removed in vacuo. The purple solid was then dissolved in 2 mL 5% TFA in MeOH and
stirred for 5 min before being recrystallized using 20 ml Et2O/hexanes (3:1, v/v). The solid
was then placed under high vacuum for one h (<150 mTorr). The final product was
obtained in 14% yield (4.3 mg) as a purple TFA salt with purity of >90%. Molecular ion
(M+H+) calculated for C35H45N2O14+: 717.2866 amu; found m/z = 717.2929 amu, error =
8.78 ppm.
2.5 References
Acton, E. M., & Tong, G. L. (1981). Synthesis and preliminary antitumor evaluation of 5iminodoxorubicin. Journal of Medicinal Chemistry, 24(6), 669-673.
Bao, L., Haque, A., Jackson, K., Hazari, S., Moroz, K., Jetly, R., & Dash, S. (2011).
Increased expression of P-glycoprotein is associated with doxorubicin
chemoresistance in the metastatic 4T1 breast cancer model. The American Journal
of Pathology, 178(2), 838-852.
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., &
Tkaczuk, K. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of
liposome-encapsulated doxorubicin and cyclophosphamide compared with
conventional doxorubicin and cyclophosphamide in a randomized, multicenter
trial of metastatic breast cancer. Journal of Clinical Oncology, 19(5), 1444-1454.
Boucek, R. J. (1997). Mechanisms for anthracycline-induced cardiomyopathy: clinical
and laboratory correlations. Progress in Pediatric Cardiology, 8(2), 59-70.

76
Burton, K. P., McCord, J. M., & Ghai, G. E. E. T. H. A. (1984). Myocardial alterations
due to free-radical generation. American Journal of Physiology-Heart and
Circulatory Physiology, 246(6), H776-H783.
Capranico, G., Kohn, K. W., & Pommier, Y. (1990). Local sequence requirements for
DNA cleavage by mammalian topoisomerase II in the presence of
doxorubicin. Nucleic Acids Research, 18(22), 6611-6619.
Cherif, A., & Farquhar, D. (1992). N-(5, 5-diacetoxypent-1-yl) doxorubicin: a new
intensely potent doxorubicin analog. Journal of Medicinal Chemistry, 35(17),
3208-3214.
Cullinane, C., & Phillips, D. R. (1993). Thermal stability of DNA adducts induced by
cyanomorpholinoadriamycin in vitro. Nucleic Acids Research, 21(8), 1857-1862.
Cummings, J., Willmott, N., Hoey, B. M., Marley, E. S., & SMyth, J. F. (1992). The
consequences of doxorubicin quinone reduction in vivo in tumour
tissue. Biochemical Pharmacology, 44(11), 2165-2174.
Cusack, B. J., Mushlin, P. S., Voulelis, L. D., Li, X. D., Boucek, R. J., & Olson, R. D.
(1993). Daunorubicin-induced cardiac injury in the rabbit: a role for
daunorubicinol?. Toxicology and Applied Pharmacology, 118(2), 177-185.
Cutts, S. M., Swift, L. P., Rephaeli, A., Nudelman, A., & Phillips, D. R. (2003).
Sequence specificity of adriamycin-DNA adducts in human tumor
cells1. Molecular Cancer Therapeutics, 2(7), 661-670.
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Del Tacca, M. (2002). Pharmacokineticpharmacodynamic relationships of the anthracycline anticancer drugs. Clinical
Pharmacokinetics, 41(6), 431-444.
Farquhar, D., Cherif, A., Bakina, E., & Nelson, J. A. (1998). Intensely potent doxorubicin
analogues: structure− activity relationship. Journal of Medicinal
Chemistry, 41(6), 965-972.
Frank, N. E., Cusack, B. J., Talley, T. T., Walsh, G. M., & Olson, R. D. (2016).
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-

77
iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac
function in a chronic rabbit model. Investigational New Drugs, 34(6), 693-700.
Frézard, F., Pereira‐Maia, E., Quidu, P., Priebe, W., & Garnier‐Suillerot, A. (2001). P‐
Glycoprotein preferentially effluxes anthracyclines containing free basic versus
charged amine. The FEBS Journal, 268(6), 1561-1567.
Govindan, S. V., McBride, W. J., Sathyanarayan, N., Mazza-Ferreira, C., & Goldenberg,
D. M. (2014). U.S. Patent No. 8,877,202. Washington, DC: U.S. Patent and
Trademark Office.
Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P., & Deeley, R.
G. (1994). Overexpression of multidrug resistance-associated protein (MRP)
increases resistance to natural product drugs. Cancer Research, 54(2), 357-361.
Gruber, B. M., Anuszewska, E. L., & Priebe, W. (2004). The effect of new anthracycline
derivatives on the induction of apoptotic processes in human neoplastic
cells. Folia Histochemica et Cytobiologica, 42(2), 127-130.
Hohl, R. J., Vestal, R. E., Holstein, S. A., Olson, R. D., Parrott, K., & Walsh, G. M.
(2013). Phase I dose-escalation clinical trial with 5-imino-13-deoxydoxorubicin in
cancer patients.
Holstein, S. A., Bigelow, J. C., Olson, R. D., Vestal, R. E., Walsh, G. M., & Hohl, R. J.
(2015). Phase I and pharmacokinetic study of the novel anthracycline derivative
5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid
tumors. Investigational New Drugs, 33(3), 594-602.
Kassner, N., Huse, K., Martin, H. J., Gödtel-Armbrust, U., Metzger, A., Meineke, I., &
Wojnowski, L. (2008). Carbonyl reductase 1 is a predominant doxorubicin
reductase in the human liver. Drug Metabolism and Disposition, 36(10), 21132120.
Kochhar, K. S., Bal, B. S., Deshpande, R. P., Rajadhyaksha, S. N., & Pinnick, H. W.
(1983). Protecting groups in organic synthesis. Part 8. Conversion of aldehydes
into geminal diacetates. The Journal of Organic Chemistry, 48(10), 1765-1767.

78
Kumar, D., Kirshenbaum, L. A., Li, T., Danelisen, I., & Singal, P. K. (2001). Apoptosis
in adriamycin cardiomyopathy and its modulation by probucol. Antioxidants and
Redox Signaling, 3(1), 135-145.
Lau, D. H., Lewis, A. D., & Sikic, B. I. (1989). Association of DNA cross-linking with
potentiation of the morpholino derivative of doxorubicin by human liver
microsomes. JNCI: Journal of the National Cancer Institute, 81(13), 1034-1038.
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic
analysis of adriamycin cardiotoxicity. Cancer, 32(2), 302-314.
Loe, D. W., Deeley, R. G., & Cole, S. P. C. (1996). Biology of the multidrug resistanceassociated protein, MRP. European Journal of Cancer, 32(6), 945-957.
Mallory, C. M., Carfi, R. P., Moon, S., Cornell, K. A., & Warner, D. L. (2015).
Modification of cellular DNA by synthetic aziridinomitosenes. Bioorganic &
Medicinal Chemistry, 23(23), 7378-7385.
Nagy, A., Armatis, P., & Schally, A. V. (1996). High yield conversion of doxorubicin to
2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity
relationship of daunosamine-modified derivatives of doxorubicin. Proceedings of
the National Academy of Sciences, 93(6), 2464-2469.
O’brien, M. E. R., Wigler, N., Inbar, M. C. B. C. S. G., Rosso, R., Grischke, E., Santoro,
A., & Orlandi, F. (2004). Reduced cardiotoxicity and comparable efficacy in a
phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®)
versus conventional doxorubicin for first-line treatment of metastatic breast
cancer. Annals of Oncology, 15(3), 440-449.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., &
Boucek, R. J. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite,
doxorubicinol. Proceedings of the National Academy of Sciences, 85(10), 35853589.
Olson, R. D., Headley, M. B., Hodzic, A., Walsh, G. M., & Wingett, D. G. (2007). In
vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy,
5-iminodoxorubicin. International Immunopharmacology, 7(6), 734-743.

79
Phillips, R. L., Kim, I. B., Carson, B. E., Tidbeck, B., Bai, Y., Lowary, T. L., & Bunz, U.
H. (2008). Sugar-substituted poly (p-phenyleneethynylene) s: sensitivity
enhancement toward lectins and bacteria. Macromolecules, 41(20), 7316-7320.
Priebe, W., Van, N. T., Burke, T. G., & Perez-Soler, R. (1993). Removal of the basic
center from doxorubicin partially overcomes multidrug resistance and decreases
cardiotoxicity. Anti-cancer drugs, 4(1), 37-48.
Robert Jr, J., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M., & Fleischer, S.
(1987). The major metabolite of doxorubicin is a potent inhibitor of membraneassociated ion pumps. Journal of Biological Chemistry, 262(33), 15851-15856.
Sawyer, D. B., Fukazawa, R., Arstall, M. A., & Kelly, R. A. (1999). Daunorubicininduced apoptosis in rat cardiac myocytes is inhibited by
dexrazoxane. Circulation Research, 84(3), 257-265.
Shen, A. L., Sem, D. S., & Kasper, C. B. (1999). Mechanistic studies on the reductive
half-reaction of NADPH-cytochrome P450 oxidoreductase. Journal of Biological
Chemistry, 274(9), 5391-5398.
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995). Probucol protects
against adriamycin cardiomyopathy without interfering with its antitumor
effect. Circulation, 91(1), 10-15.
Smith, T. H., Fujiwara, A. N., & Henry, D. W. (January 01, 1978). Adriamycin
analogues. 2. Synthesis of 13-deoxyanthracyclines. Journal of Medicinal
Chemistry, 21, 3, 280-3.
Streeter, D. G., Johl, J. S., Gordon, G. R., & Peters, J. H. (1986). Uptake and retention of
morpholinyl anthracyclines by adriamycin-sensitive and-resistant P388
cells. Cancer Chemotherapy and Pharmacology, 16(3), 247-252.
Studenovsky, M., Ulbrich, K., Ibrahimova, M., & Rihova, B. (2011). Polymer conjugates
of the highly potent cytostatic drug 2-pyrrolinodoxorubicin. European Journal of
Pharmaceutical Sciences, 42(1), 156-163.
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients
treated with doxorubicin. Cancer, 97(11), 2869-2879.

80
Taatjes, D. J., Fenick, D. J., & Koch, T. H. (1998). Epidoxoform: A hydrolytically more
stable anthracycline− formaldehyde conjugate toxic to resistant tumor
cells. Journal of Medicinal Chemistry, 41(8), 1306-1314.
Takahashi, Y., Kinoshita, M., Masuda, T., Tatsuta, K., Takeuchi, T., & Umezawa, H.
(1982). 3'-deamino-3'-morpholino derivatives of daunomycin, adriamycin and
carminomycin. The Journal of Antibiotics, 35(1), 117-118.
Tehrani, K. A., D'hooghe, M., & De Kimpe, N. (2003). Novel synthesis of indolizidines
and quinolizidines. Tetrahedron, 59(17), 3099-3108.
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984). Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase
II. Science, 226(4673), 466-468.
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A., &
Kalyanaraman, B. (1997). Endothelial nitric oxide synthase-dependent superoxide
generation from adriamycin. Biochemistry, 36(38), 11293-11297.
Verweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., & Judson, I.
R. (2000). Randomized phase II study of docetaxel versus doxorubicin in first-and
second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas
in adults: a study of the European Organization for Research and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical
Oncology, 18(10), 2081-2086.
Weiss, R. B. (1992, December). The anthracyclines: will we ever find a better
doxorubicin?. In Seminars in Oncology (Vol. 19, No. 6, pp. 670-686).
Yang, D., & Zhang, C. (2001). Ruthenium-catalyzed oxidative cleavage of olefins to
aldehydes. The Journal of Organic Chemistry, 66(14), 4814-4818.

81

CHAPTER THREE: HYDRAZONE REDUCTIONS FOR IMPROVEMENT OF
DIDOX YIELD
3.1 Introduction
The anthracycline doxorubicin (DOX) is an extensively used anticancer agent
(Figure 3.1). However, it is plagued by dose-dependent cardiotoxicity stemming from two
structural moieties: the C-13 carbonyl and the quinone (Boucek, 1997; Cusack, 1993).
Enzymatic reduction of DOX’s carbonyl, mediated by carbonyl reductase, forms an alcohol
metabolite that accumulates in cardiac tissue and disrupts function by inhibiting ion pumps
(Robert Jr, 1987). In addition, DOX’s quinone catalyzes the production of reactive oxygen
species that disproportionately damages cardiac myocytes (Cummings, 1992).

Figure 3.1
Structure of Doxorubicin and the non-cardiotoxic DIDOX analog. Both
the C-13 carbonyl and quinone of doxorubicin produce cardiotoxicity. The carbonyl is
reduced by carbonyl reductase to form a cardiotoxic C-13 alcohol and the quinone
catalyzes the formation of reactive oxygen species. The structure of DIDOX is analogous
to DOX except the carbonyl is completely reduced to a methylene and the quinone has
been altered to an iminoquinone.
Previous work has been successful at alleviating this terrible side effect by reducing
the carbonyl to a methylene and converting the quinone to an iminoquinone, producing 5-
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imino-13-deoxydoxorubicin (DIDOX). However, conversion of doxorubicin to DIDOX
has been hindered by a poor method for the reduction of the C-13 carbonyl to generate the
intermediate 13-deoxydoxorubicin (DeoxyDOX). The current method employs a WolffKishner style reduction comprised of an initial condensation of benzene sulfonylhydrazide
onto DOX’s carbonyl to afford BSHDOX, followed by treatment with NaBH3CN and
pyridinium p-toluenesulfonate (PPTS) (Scheme 3.1) (Walsh, 2007; Zhang, 1999). The
reduced anthracycline, after these two steps, is generally produced in very low yields that
range from 5-35% (Smith, 1978).
It was hypothesized that using a different hydrazone during the reduction could
potentially help improve overall yield. In these experiments, six different hydrazones were
formed and each reduced under similar conditions. The deoxygenated products were not
able to be purified and isolated as it required expensive and non-available preparative
HPLC. In light of this, the yield of each reaction is reported as a relative abundance (RA),
determined by analytical HPLC, in order to compare the hydrazone reductions. It was
found that the current hydrazone used for the reduction produced only 43% RA, whereas
four alternate hydrazones produced up to 59% RA. This data suggests that the current
method to synthesize DeoxyDOX could be improved by a simple adaptation to a different
hydrazone.
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Scheme 3.1 DIDOX Synthesis. Condensation of DOX and NH2NHSO2Ph affords
BSHDOX. It then follows a Wolff-Kishner style reduction to produce DeoxyDOX in 535% yield. Lastly, the quinone is converted to an iminoquinone using concentrated
ammonia.
3.2 Results and Discussion
In this work, a series of six different hydrazone formation/reductions were
performed to optimize the relative formation of DeoxyDOX, as determined by HPLC. Four
of the hydrazone reductions attempted appeared to outperform the conventional
commercial method. It was found that more electron-withdrawing hydrazones were able to
undergo reduction at a much faster rate. Nevertheless, a temperature of 70 °C was required
in order for the reduction reactions to go to completion.
In order to test the impact of the aromatic ring on the reduction step, it was
determined that six different hydrazones of varying electronic characteristics needed to be
evaluated. Three of the precursor hydrazides were commercially available and the
remaining three required a simple, one step preparation. The syntheses of 4fluorobenzenesulfonohydrazide (FSH), 4-(trifluoromethyl) benzenesulfonohydrazide
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(TFSH) & pyridine 3-sulfonylhydrazide (PSH), shown in Figure 3.2, were performed
using identical methods, which involved chilling to -30 °C in THF and substituting their
respective chlorides using hydrazine (Myers, 1997). Purification of these hydrazides was
accomplished by simple extraction and recrystallization. The hydrazide, PSH, was difficult
to obtain in high yields using this method, possibly due to increased solubility in water and
loss of material during workup and preliminary extraction steps. While it was not attempted
in this work, a back extraction in the future may be able to improve the yield.

Figure 3.2
Synthesis of hydrazides and DOX-hydrazone. (A) Hydrazine is used to
displace chlorine during the formation of hydrazides. (B) Shown is the attachment of BSH
onto DOX through condensation. The formation of the five other DOX-hydrazones were
all isolated using analogous conditions and in similar yields.
The other three hydrazides—benzenesulfonylhydrazide (BSH), tosylhydrazide
(TSH), and 4-nitrobenzenesulfonohydrazide (NSH)—were purchased from commercial
sources.
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Attachment of the six hydrazides used the same reaction conditions (Figure 3.2).
First, DOX was dissolved in MeOH and then the corresponding hydrazide was added and
allowed to react at 40 °C overnight under nitrogen. After recrystallization, the DOXhydrazones were isolated in nearly 100% yield. The hydrazones FSH, TFSH, NSH, and
PSH were thought to be more electron-withdrawing than BSH and thus might possibly be
easier to reduce. To obtain a broader representation, TSH was also considered because of
its slight electron-donating ability.
The six distinct DOX-hydrazones were then reduced to DeoxyDOX using
NaBH3CN and PPTS at 70 °C (Figure 3.3). The reaction progress was monitored using
LC-MS to determine the required time for all of the starting hydrazone to no longer be
present. Only BSHDOX required more than 60 minutes to be completely consumed. In
fact, it took nearly three times as long as the next slowest hydrazone reduction.
Interestingly, this is the hydrazone currently used to prepare DIDOX (Walsh, 2007). One
apparent trend seen with this data is that more electron-withdrawing hydrazones produced
less DeoxyDOX and more of the main side product. For example, all starting NSHDOX
was consumed after only 30 minutes under reductive condition, but produced significantly
less DeoxyDOX than the reduction of TSHDOX, which required twice the time.
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Figure 3.3
DOX-Hydrazone reductions. (A) Shown is the Wolff-Kishner reduction
of BSHDOX to DeoxyDOX using NaBH3CN and PPTS, at 70 °C. The time required for
complete reduction was found to be 160 minutes and there was 43% RA of DeoxyDOX
formed. (B) These five hydrazones were reduced using similar methods as shown for
BSHDOX and are ordered by decreasing percent RA DeoxyDOX. Interestingly, as the
hydrazones become more electron-withdrawing, the RA of DeoxyDOX formed becomes
smaller.
The relative abundance (RA) for DeoxyDOX formation was determined
immediately following reduction completion. It was found that only one DOX-hydrazone,
PSHDOX, produced less relative DeoxyDOX than the currently used BSHDOX. The RA
of DeoxyDOX formed using BSHDOX was 43%, while it increased to 59% when using
TSHDOX. This was slightly surprising, as the only difference between BSH and TSH is a
methyl group at the para-position. Nonetheless, TSH outperformed the other, more
electron-withdrawing hydrazones. The lower abundance of DeoxyDOX formation from
the BSHDOX reduction can be explained by the lengthy 160 minutes in these reaction
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conditions, which allows for the formation of numerous side products not observed with
any other hydrazones (Figure 3.4). Along with lower abundance, these impurities could
potentially make purification using BSH much more difficult than the other hydrazones.

Figure 3.4
HPLC chromatograms of DOX-hydrazone reductions. The above
chromatograms were obtained using HPLC at a wavelength 480 nm and ordered by RA of
DeoxyDOX formed after reduction. DeoxyDOX is shown with a red arrow and elutes just
after 4 minutes as the main product in all chromatograms. The main side product elutes
just after DeoxyDOX and increases as the RA of DeoxyDOX decreases, BSHDOX being
the exception.
Reduction of these DOX-hydrazones all exhibited the formation of a distinct and
prominent side product that elutes between 4.5-5.0 minutes on HPLC, just after the elution
of DeoxyDOX. It has not yet been structurally characterized, but it appears to be the main
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side product formed and the quantity produced varies greatly depending on which
hydrazone was used. Interestingly, the observed m/z for this side product, 599.16 amu, is
the same regardless of the hydrazone used, suggesting an analogous impurity. Also, it
appears that more of this side product forms as the electron-withdrawing effects increase.
Initially, it was thought that the impurity was an intermediate that had not yet been fully
reduced, however, prolonging the reduction following complete consumption of the
starting hydrazone proved insufficient to decrease the side product. Future work will need
to focus on characterizing and identifying the root source of this side product to better
optimize the reaction.
An understanding of the reduction mechanism may allow for explanation of the
accelerated reaction time seen with the electron-withdrawing hydrazones, as shown in
Scheme 3.2 (Kosower, 1992; Miller, 1989). Initially, treatment with an acid produces the
iminium, which is then reduced by NaBH3CN. Next, elimination of the sulfonyl group
(SG) produces a diazene, which is readily deprotonated to form a diazenyl anion. Finally,
this anion decomposes to N2 and a carbanion, followed by protonation to form the reduced
methylene. The rate of this initial step has been monitored using LC-MS and has shown
that formation of the hydrazine-DOX occurs at similar rates for all the hydrazones.
However, it is thought that elimination of more electron-withdrawing SG’s occur much
faster than that of TSH and BSH, allowing for quicker decomposition to the methylene. On
the other hand, while these increased reduction rates may be appealing, they are hampered
by an increased production of the main side product.
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Scheme 3.2 Mechanism of hydrazone reduction. The mechanism for reduction
follows this route. It is initiated by the formation of an iminium, followed by NaBH3CN
reduction. At this point, the SG is eliminated and decomposition produces the reduced
methylene.
3.3 Conclusion
The traditional BSHDOX used during the synthesis of DeoxyDOX has been shown
in these experiments to be the suboptimal choice. All but one DOX-hydrazone appeared to
yield higher quantities of DeoxyDOX than the commercially employed BSHDOX, which
was determined by comparing RA. One straightforward possibility as to why this occurred
could simply be attributed to the fact that the necessary time in order for a full reduction of
BSHDOX was significantly longer than that for all other hydrazones. A longer reaction
time could potentially facilitate the production of more side products, such as the removal
of the daunosamine sugar moiety through acid-catalyzed hydrolysis. Conversely, the more
rapid reductions from electron-withdrawing sulfonyls produced a significant quantity of
undesired side products as well. From these results, it was determined that an inverse
relation existed between the strength of electron-withdrawing hydrazones and relative
DeoxyDOX formed. The exception to this being BSH, due to the prolonged reaction time,
which creates additional impurities.
In the future, alternative methods for carbonyl reduction will be investigated to
further improve the synthesis of DIDOX. Two potential options would be the implemention
of a Clemmensen reduction or Lewis acid ionic hydrogenation (Goddard-Borger, 2007;
Kursanov, 1974; Luchetti, 1991). The general mechanism of the Clemmensen reduction
involves replacement of the carbonyl with a methylene through radical rearrangements
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using zinc (Scheme 3.3). Specifically, both zinc and the carbonyl donate a single electron
to form a zinc-oxygen bond, which displaces a radical onto the tertiary carbon. Next, that
radical and an electron from a second zinc combine, then an additional two-electron
donation removes zinc oxide from the compound. The newly formed zinc carbenoid is then
removed after the addition of acid. In contrast, Lewis acid (LA) coordination during ionic
hydrogenation enhances carbonyl electrophilicity, which allows for reduction using a
hydride source. Implementation of these methods may improve the yield of DeoxyDOX
over the currently used Wolff-Kishner approach. However, there are several potential
issues with these two methods. One problem would be the inadvertent acid-catalyzed
hydrolysis of the daunosamaine glycosidic bond during the Clemmensen reduction. Overreduction may also be an issue with the LA, since reduction of the quinone carbonyl or
various hydroxyl moieties of DOX may occur. As such, further investigation will be
required to determine the optimal method toward producing the methylene present in
DeoxyDOX.
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Scheme 3.3 Alternative carbonyl reductions to produce DeoxyDOX. (A) During the
Clemmensen reduction, both the carbonyl and zinc donate a single electron to form a zincoxygen bond which forces the other carbonyl electron onto the tertiary carbon. Next, this
carbon radical and an electron from a second zinc come together to form a zinc-carbon
bond. Ensuing radical rearrangement, ZnO is removed by forming a zinc carbenoid that
readily reduced using an available acid, such as HCl. (B) Dehydrogenation using a Lewis
acid, such as AlCl3, begins by coordinating with the carbonyl, making the attached carbon
significantly more electrophilic and available for hydride reduction. After the first
reduction, another Lewis acid will coordinate with the oxygen and allow for a second
hydride reduction to occur.
3.4 Materials and Methods
3.4.1 Materials and Reagents
Doxorubicin hydrochloride was purchased from Advanced ChemBlocks, Inc.
Pyridinium p-toluenesulfonate (PPTS), sodium cyanoborohydride, and tosylhydrazide
were

purchased

from

fluorobenzenesulfonyl

Aldrich
chloride

chemicals.
were

Benzenesulfonylhydrazide

supplied

by

TCI.

and

4-

4-(Trifluoromethyl)

benzenesulfonyl chloride and pyridine-3-sulfonyl chloride were purchased from Matrix
Scientific. Hydrazine monohydrate was acquired from Beantown Chemical. 4-
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Nitrobenzenesulfonohydrazide came from Combi-Blocks. All solvents were purchased
from Fisher Scientific unless otherwise specified.
3.4.2 Equipment
NMR data was acquired using either 600 MHz Bruker Avance III 600 coupled with
Bruker Ultrashield 600 Plus or 300 MHz Bruker Ultrashield 300 coupled with Bruker
Avance III 300. HPLC chromatography was performed using Agilent 1100 series equipped
with 50x4.6 mm Hypersil Gold Phenyl column having 5µm pore size. A Bruker HCTultra
ETD II Ion Trap was used for mass spectrometry.
3.4.3 Experimental
4-fluorobenzenesulfonohydrazide
4-fluorobenzenesulfonyl chloride (514.2mg, 2.64mmol) was made to be 0.5M in THF
(5.3mL) and allowed chilled to -30°C. Hydrazine (208mL, 6.61mmol, 2.5eq) was then
added via syringe. This was allowed to react at -30°C and monitored by TLC using
EtOAc/Hexanes (2:1, v/v). Starting material had all reacted after 30 minutes. Solution was
then diluted with 10mL EtOAc and washed with 10 mL ice-cold 10% NaCl aqueous
solution x5. It was then dried using sodium sulfate and filtered. The solution was then
slowly added over 5 minutes to 30mL hexanes and allowed to stir for 15 minutes. The
precipitate was then collected by vacuum filtration and washed with 15mL hexanes x3.
The final product, 4-fluorobenzenesulfonohydrazide, was collected as a white powder and
placed under high vacuum (>150mTorr) for 90 minutes (338.5mg, 67.4% yield). 1H NMR
(CDCl3 with 0.03% v/v TMS, 600 MHz) 7.98-7.94 (m, 2H), 7.25 (t, 2H, J = 8.6 Hz),
5.59 (s, 1H), 3.63 (s, 2H)
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4-(Trifluoromethyl) benzenesulfonohydrazide
Synthesis

followed

procedures

analogous

as

stated

above

for

4-

fluorobenzenesulfonohydrazide. Final product was obtained in 88% yield as a white
powder. 1H NMR (C2D6OS with 0.03% v/v TMS, 300 MHz) 8.65 (s, 1H), 8.00 (s, 4H),
4.29 (s, 2H).
Pyridine 3-sulfonylhydrazide
Synthesis

followed

procedures

analogous

as

stated

above

for

4-

fluorobenzenesulfonohydrazide. Final product was obtained as a white powder in in 22%
yield. 1H NMR (C2D6OS with 0.03% v/v TMS, 300 MHz) 8.93 (dd, 1H, J = 2.4 Hz, 0.8
Hz), 8.82 (dd, 1H, J = 4.8 Hz, 1.6 Hz), 8.61 (br, 1H), 8.16 (ddd, 1H, J = 8.0 Hz, 2.4 Hz, 1.6
Hz), 7.65 (ddd, 1H, J = 8.0 Hz, 4.8 Hz, 0.8 Hz), 4.311 (br, 2H).
Tosylhydrazone DOX HCl
DOX HCl (40.0mg, 0.0709mmol) was made to be 0.02M in MeOH (3.5mL) before tosyl
hydrazide (29.1mg, 0.156mmol, 2.2 eq) was added. This was allowed to react at 50 °C
overnight. When starting material had completely reacted (determine by LC-MS) it was
removed from heat and allowed to cool to RT. The product was then recrystallized by
slowly adding 15mL MTBE/hexanes (4:1, v/v) and allowed to stir for 15 minutes at RT.
The solid was then isolated by centrifuge (1800 rpm, 10 minutes, 4 °C) and placed under
high vacuum (>150mTorr) for 60 minutes. Hydrazone DOX was collected as a red solid in
greater than 95% purity and ~100% yield.
Synthesis of Additional DOX-Hydrazones
The other 5 hydrazones, BSHDOX, FSHDOX, TFSHDOX, NSHDOX, and PSHDOX
were formed using similar procedures and in similar yields as tosylhydrazone DOX HCl.
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Hydrazone Reductions
Tosylhydrazone DOX HCl (47.2mg, 0.0631mmol) was dissolved in 1mL MeOH. PPTS
(95.1mg, 0.379mmol, 6eq) and NaBH3CN (39.7mg, 0.631mmol, 10eq) were combined and
dissolved in 2.2mL MeOH (DOX was made to be 0.02M in MeOH overall) before being
added to DOX. This was allowed to react at 70 °C until starting hydrazone had been
completely reduced (60 minutes). Monitored via LC-MS. No purification was attempted,
however a RA of DeoxyDOX formation was obtained through HPLC analysis.
All hydrazone reductions followed these procedures (with varying times to obtain
full reduction).
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APPENDIX A: 1H NMR SPECTRA
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APPENDIX B: 13C NMR SPECTRA
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APPENDIX C: MASS SPECTROMETRY
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APPENDIX D: HPLC CHROMATOGRAMS
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